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ABSTRACT
Opioid misuse relating to prescription pain killers have claimed the lives of many Americans,
posing an escalating nationwide public health crisis. Prescription opioid overdose and death can
impair an individual’s functionality, destabilizes family, and impose a significant financial
burden. In 2014, the U.S. had an estimated 36 million people ages 12 years and older who had
used prescription opioids for non-medical reasons. In that same year, there were “28,647” (61%)
of 47,055 prescription and non-prescription opioid overdose deaths, indicating an increase from
previous years (Center for Disease Control (CDC, 2020). Several measures to address the opioid
crisis have been implemented, but opioid overdose remains a problem. This integrative review
explored diverse relevant literature addressing the opioid epidemic, focusing on the prescription
drug monitoring program (PDMD), as having the potential to address this epidemic through the
increased reporting of data. The PDMP is a national database that stores data from pharmacies
and prescribers on controlled substances dispensed to patients, to safeguard opioid prescribing
practice. Clinicians can use PDMPs to identify patients exhibiting risky behaviors indicating
prescription drug addiction, overdose risk or diversion, and potential doctor shopping (Hawk et
al., 2018). Vital data obtained from the PDMP must be reported to the health insurance
companies, state licensing boards, law enforcement, local health departments, treatment centers,
and other relevant entities to facilitate early interventions, and allocation of resources for quality
care.
Keywords: prescription opioid misuse, opioid dependence, overdose deaths, prescription
drug monitoring program (PDMP), safe prescribing practices.

INCREASED REPORTING OF PDMP DATA TO ADDRESS OPIOID MISUSE

4

Copyright Page
All rights reserved. This integrative review is the sole work of the author. No part of this work
may be reproduced in any form without written permission from the copyright owner.

INCREASED REPORTING OF PDMP DATA TO ADDRESS OPIOID MISUSE

5

Dedication
This DNP scholarly project is dedicated to my late grandmother Hannah Cyrpian Shaw,
who strongly believed in the fear of God, education, and women empowerment. She encouraged
me to make the best of myself and advance to higher heights as best as I can, and I have not
fallen short of her expectations. Unfortunately, she is not here to witness this greatest
achievement, but I know that she is smiling down at me from heaven, saying “a job well done.”

INCREASED REPORTING OF PDMP DATA TO ADDRESS OPIOID MISUSE

6

Acknowledgments
First and foremost, I want to acknowledge the Almighty God, who has guided me through this
process to accomplish my goal. I also want to thank all of my professors especially Dr. Sanders
(project chair), Dr. Kennedy (practicum professor), Dr. Goodrich, and Dr. Kopis for their
continuous encouragement and faith in me. A special thanks to Ms. Faith Sterling for her
patience in accommodating my practicum experience. I also want to thank Dr. Conton and the
staff of Raven Counselling for allowing me my practicum experience towards the completion of
my DNP degree.
A special thanks go to my family, my husband, Denzil, and my three sons Dwayne,
Dunstan, and Delphaneaux, my parents, Milford and Victoria, my siblings, in-laws, and coworkers, classmates, and friends for their patience, support, and accommodation throughout this
DNP journey. I also want to thank the Snellville United Methodist Church Stephen Ministry and
the sanctuary choir for their constant support and encouragement throughout this journey. To
God Be the Glory.

INCREASED REPORTING OF PDMP DATA TO ADDRESS OPIOID MISUSE

7

Table of Contents

Acknowledgments……………………………………………………………………………………………………………………………….6
List of Tables……………………………………………………………………………………………………………………………………….9
List of Figures…………………………………………………………………………………………...10
List of Abbreviations…………………………………………………………………………………....11
SECTION ONE: FORMULATING THE REVIEW QUESTION (Level 1 Heading)……………………12
Introduction (Level 2 Heading)……………………………………………………………………..12
Defining Concepts and Variable (Level 2 Heading)…………………………………………………………………..13
Prescription Opioid Crisis……………………………………………………………………..14
Contributory Factors to the Opioid Crisis…………………………………………………....15
Strategies to Address the Opioid Crisis………………………………………………………16
The Prescription Drug Monitoring Program………………………………………………...18
The PDMP Framework………………………………………………………………………..20
Rationale for Conducting the Review (Level 2 Heading)………………………………………….24
Purpose (Level 2 Heading)…………………………………………………………………………..24
The Review Question (Level 2 Heading)…………………………………………………………....22
Inclusion and Exclusion Criteria (Level 2 Heading)………………………………………………24
PRISMA flow Diagram (Level 2 Heading)…………………………………………………………24
Conceptual Framework (Level 2 Heading)…………………………………………………………25
SECTION TWO: COMPREHENSIVE AND SYSTEMATIC SEARCH (Level 1 Heading)………..27
Search Organization and Reporting Strategies (Level 2 Heading)……………………………….27
Terminology (Level 2 Heading)……………………………………………………………………..27
SECTION THREE: MANAGING AND COLLECTING DATA (LEVEL 1 Heading)……………28
SECTION FOUR: QUALITY APPRAISAL (Level 1 Heading)…………………………………….28
Sources of Bias (Level 2 Heading)…………………………………………………………………..30
Appraisal Tools (Literature Matrix) (Level 2 Heading)…………………………………………..31
Applicability of Results (Level 2 Heading)…………………………………………………………31
Reporting Guidelines (Level 2 Heading)……………………………………………………………32
SECTION FIVE: DATA ANALYSIS AND SYNTHESIS (Level 1 Heading)………………………………...33
Data Analysis Methods (Level 2 Heading)………………………………………………………….33

INCREASED REPORTING OF PDMP DATA TO ADDRESS OPIOID MISUSE

8

Synthesis of Results (Level 2 Heading)……………………………………………………………..37
Contributory Factors to the Opioid Crisis………………………………………………….. 37
Strategies to Address the Opioid Crisis……………………………………………………….41
The Prescription Drug Monitoring Program (PDMP)……………………………………….46
Ethical Considerations (Level 2 Heading)...………………………………………………………...52
TIMELINE………………………………………………………………………………………………52
SECTION SIX: DISCUSSION (Level 1 Heading)…………………………………………………………………………..53
Implication for Practice (Level 2 Heading)…………………………………………………………………………………54
Dissemination (Level 2 Heading)…………………………………………………………………………………………………..56
DNP Essentials (Level 2 Heading……………………………………………………………………56
Conclusion………………………………………………………………………………………………..59
References …………………………………………………………………………………………………………………………………………..61

INCREASED REPORTING OF PDMP DATA TO ADDRESS OPIOID MISUSE

9

List of Tables
1. Table 1 inclusion and exclusion table…………………………………………………...23
2. Table 2. Data Analysis…………………………………………………………………..36
3. Appendix A Melnyk Table of Evidence……………………………………...................68

INCREASED REPORTING OF PDMP DATA TO ADDRESS OPIOID MISUSE

10

List of Figures
1. Figure 1 The PDMP Flowsheet……………………………………………………20
2. Figure 2 PRISMA Flow diagram…………………………………………………..24
3. Figure 3. Summary of the contributory factors to the opioid crisis………………..37
4. Figure 4. Summary of strategies to address the opioid crisis………………………45
5. Figure 5. Summary of PDMP………………………………………………………51
6. Appendix B PRISMA Flow diagram……………………………………………….90
7. Appendix C IRB email ……………………………………………………………..91
8. Appendix D Collaborative Institutional Training Initiative (CITI) Certificates…..92-94

INCREASED REPORTING OF PDMP DATA TO ADDRESS OPIOID MISUSE

List of Abbreviations
American Association of Colleges of Nursing (AACN)
American Psychology Association (APA)
Center for Disease Control (CDC)
Drug Enforcement Administration (DEA)
Doctor of Nursing Practice (DNP)
Emergency Department (ED)
Human Immunodeficiency Virus (HIV)
Institutional Review Board (IRB)
Licensed Clinical Social Worker (LCSW)
Medication-Assisted Treatment (MAT)
Meta-analysis (MA)
Neonatal Opioid Withdrawal Syndrome (NOWS)
Opioid Use Disorder (OUD)
Prescription Drug Monitoring Program (PDMP)
Randomized Controlled Trials (RCTs)
Systemic Review (SR)

11

INCREASED REPORTING OF PDMP DATA TO ADDRESS OPIOID MISUSE

12

SECTION ONE: FORMULATING THE REVIEW QUESTION
Introduction
The 1980s marked the era during which pain management with opioids was considered
inadequate for cancer pain and postoperative patients, leading to the concept of pain as the fifth
vital sign. Launched by the American Pain Society in 1995, this concept was used to evaluate
and treat pain symptoms (Kelly et al., 2016). In 2000, the Joint Commission further incorporated
this concept into their published standards for pain management. The focus was on pain
management and less on regulatory guidelines on opioid prescriptions and its addictive effects.
This led to the unintended consequences of the current opioid epidemic (Kelly et al., 2016).
Prescription opioid abuse, also referred to as opioid use disorder (OUD) is a leading
cause of accidental deaths in the United States (U.S.), and escalating public health concern with a
significant economic burden. A study by “Neville & Foley (2020),” revealed that in 2018, the
opioid epidemic-related cost to the U.S was estimated at $631 billion. It is estimated that 822,000
people in the U.S. were treated for opioid misuse, leading to the implementation of public health
initiatives to limit opioid abuse and provide interventions to individuals affected (Reinhart et al.,
2018). Despite its negative effects, opioids have multiple benefits in treating cancer pain, chronic
pain, surgical pain, and other medical conditions. However, prolonged use of opioids can lead to
overuse, dependency, addiction, and deaths, creating a strong link to illicit drugs, such as
fentanyl, and heroin because of its availability, affordability, and an intense high effect
(McDonald et al., 2019). Consequently, the U.S. still faces challenges to adequately address the
opioid crisis, compounded by less skilled providers, fewer treatment programs, and limited
access to behavioral health services (Goedel et al., 2019). Several measures have been employed
to combat the opioid crisis; however, misuse and overdose remain relatively high.
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According to the Center for Disease Control and Prevention (CDC, 2020), the PDMP has
a promising future as an interventional tool to improve opioid prescribing at the state level,
improve clinical practice, decrease the use of multiple providers, and protect the at-risk patient
from harm (CDC, 2020). Several challenges, however, have been identified with the use of the
PDMP, such as inefficiency among prescribers, inconsistency and faulty prescribing practices,
difficulty with ease of use, untransmitted data from the electronic medical record (EMR), and
inadequate reporting of PDMP data have hindered the efficient use of the PDMP. In examining
the clinical question “How can prescription opioid misuse be addressed through the increased
reporting of prescription drug monitoring program (PDMP) data?” This integrative review
explored literature with great significance to the topic of discussion.
Defining Concepts and Variables
There is no doubt that the opioid epidemic is a major public health crisis, and despite
several strategies to combat it, the occurrence of opioid abuse, overdose, addiction, and opioidrelated deaths is alarming. Addressing prescription opioid misuse through the increased reporting
of PDMP data to health insurance companies, state health departments, law enforcement,
licensing boards (CDC, 2020), and other relevant entities will facilitate early interventions for
victims of opioid use disorder (OUD). This can also trigger the allocation of resources to train
skilled providers and facilitate the availability and access to treatment facilities. However, there
are complexities involved in addressing the prescription opioid crisis. Therefore, variables such
as the contributory factors to opioid misuse, strategies to address opioid misuse, and the
efficiency of the PDMP, must all be carefully examined to assess their impact on the topic of
discussion in answering the clinical question.
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Prescription Opioid Crisis
Prescription opioids are commonly used to treat both chronic and acute pain for better
pain management and improved quality of pain care across the clinical settings. Among the most
over-prescribed opioids are oxycodone, hydrocodone, and fentanyl, which have greatly
contributed to the epidemic of prescription opioid misuse and deaths (Lyapustina et al., 2017).
When appropriately used, prescription opioid therapy could be an important component of
treatment (Yang et al., 2018); however, serious fatal and non-fatal consequences are associated
with its misuse (Goedel et al., 2019). Approximately, 46 people die daily from a prescription
opioid-related overdose, with the greatest use among ages 18 to 25 (CDC, 2020). The opioid
crisis is believed to have occurred in three waves, starting with prescription opioids in 1999,
followed by heroin usage in 2010, and then by the illicit manufacturing of synthetic opioids such
as fentanyl, in 2013 (Neville & Foley, 2020).
Prescription opioids contribute to the increasing epidemic in the U.S, with more than
35% of opioid overdose-related deaths, in 2017 (CDC, 2020). Compared to non-Hispanic blacks
and Hispanics, a significant increase in prescription opioid overdose rates was identified among
individuals ages 65 years of age, and a higher overdose rate reported among non-Hispanic whites
and American Indians or Alaskan Natives. The prescription overdose rate among men was 6.1
per 100,000 people, and the rate among women was 4.2 per 100,000 (CDC, 2020). There is also
an increase in opioid misuse among pregnant women leading to increasing neonatal opioid
withdrawal syndrome (NOWS) in newborns. Additionally, opioid misuse is associated with an
increased risk of contracting the hepatitis C virus and human immunodeficiency virus (HIV)
(Stuart et al., 2018).
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Contributory Factors to the Prescription Opioid Crisis
The intent to adequately manage patients’ pain in the 1980s led to the concept of pain as
the fifth vital sign. The increased use of painkillers to address this notion had spiraled into the
unintended consequence of the opioid crisis. Likewise, pharmaceutical advertising and
prescription practices have greatly contributed to the prescription opioid crisis (Kelly et al.,
2016). During late 1990 to 2000, pharmaceutical companies falsely advertised and marketed
their products to the medical community and the public as being less addictive. Consequently,
this increased prescribing of painkillers by healthcare providers gradually led to the widespread
misuse of both prescription and non-prescription opioids. Unintentionally, prescribers partly
contributed to this epidemic by unsafe prescribing, due to lack of access to a universal medical
record system for verification, at that time.
This has resulted in uncoordinated care and diversion for misuse because patients with
risky drug-seeking behaviors can obtain multiple prescriptions from different unknowing
prescribers, in an illegal practice called “doctor shopping” (McDonald et al., 2019). Data
analysis from a cross-sectional National Survey on Drug Use and Health (NSDUH), as reported
by SAMSHA, (2016), discovered that from 2016 through 2017, 12% of prescription opioid users
attested to misusing prescription opioids. It was discovered that 27% of these individuals
exclusively misused their prescribed opioids, whereas 38% only misused prescription opioids
without prescriptions, and 31% misused prescription and non-prescription opioids combined,
leaving the remaining 4% as unclassified (SAMHSA, 2016). Opioid overuse and addiction affect
each state differently, resulting in a wide variation of overdose death rates among states, making
it a compounded problem. Opioid prescription guidelines also vary among states leading to
inconsistencies and risky practices.
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Patient satisfaction-based incentives and their influence on prescribers’ performance also
contributed to faulty prescribing practices in fear of earning poor ratings (Carrico et al., 2018).
Additionally, emergency department physicians feel pressured to prescribe opioid analgesics to
avoid administrative and regulatory interrogations. The high emphasis placed on patient
satisfaction scores hinders prescribers’ pain management strategies of drug-seeking patients,
leading to increased and unnecessary prescriptions (Kelly et al., 2016). Consequently, increased
opioid prescriptions contributed to increased opioid addiction (Young et al., 2018).
Strategies to Address the Opioid Crisis
Strategies to address the opioid crisis have been initiated at the local, state, and federal
levels. The opioid crisis has been declared a public health emergency by the Trump
administration. Policymakers are, therefore, working on a range of strategies, including
pharmacological and psychosocial regimens, access to treatment and rehabilitation services, and
the effective use of the prescription drug monitoring programs (PDMP). In March 2018, a federal
spending bill including a $3.3 billion increase in funding was passed by Congress to support
opioid prevention, treatment regimen, and law enforcement activities for state and local
governments (America Nurses Association (ANA), 2018). Under the Obama administration, the
21st Century Cures Act of $1 billion was passed to assist states against the opioid epidemic. This
funding supported increased access to treatment, increased treatment needs, and reduced opioidrelated overdose deaths (ANA, 2018).
Strategies to address the prescription opioid crisis include medication-assisted therapy
(MAT) with drugs such as naloxone to reverse overdose effects and methadone to reduce
cravings and withdrawals (Lagisetty et al., 2017). In addition to MAT, psychosocial therapy can
also be implemented as an intervention for opioid misuse (Jefferies, 2018). Alternative therapies
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such as behavioral interventions and education must be offered to clients about the dangers of
opioid misuse, and rehabilitation services provided for individuals struggling with opioid
addiction (Coffin, et al., 2017). Prescribers should conduct thorough assessment and screening of
clients to identify contributory factors to opioid abuse, and hindrances to abstinence.
Furthermore, mental health status should be assessed and documented for the provision of safe,
quality care (Neville & Foley, 2020).
The drug take-back programs are initiatives to raise awareness on the safe disposal and
return of unused prescriptions to limit the number of unused narcotics in the community. Some
locations, such as the fire station or police department have trained coaches who can assess
individuals and direct them to seek help. The success of this initiative to control opioid overdose
and diversion, remain unknown. Patients are also taught the proper disposal of unused narcotics
at home. However, most claimed they have not been properly taught, and usually leave unused
prescriptions around the house or are disposed of in the trash can, creating a risk for diversion,
(Bonnie et al., 2017). Prevention, however, is the most important strategy to address the opioid
crisis, and educating healthcare providers, patients, and family, and the entire community about
the dangers of opioid misuse and addiction is crucial (Turner et al., 2019).
The ANA is in collaboration with more than 40 groups of providers, committed to
increasing opioid prescriber training, and improve access to treatment. Three major areas were
also targeted which are: opioid prescribing practices, expanded use of naloxone, and expansion
of medication-assisted treatment to reduce opioid misuse and overdoses (ANA, 2018).
Collaboratively, the ANA is working with its constituents and state nurses’ associations to have
more registered advanced practice nurse (APRN) prescribers and raise awareness about the
significance of the Prescription Drug Monitoring Programs (PDMPs).
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The Prescription Drug Monitoring Program (PDMP)
The PDMP is a national database for screening patients exhibiting risky behaviors
suggesting prescription drug addiction, overdose risk or diversion, and potential doctor shopping.
It provides information on the type of medication prescribed, the reason for the prescription, the
prescriber, and the location and time it was dispensed (Wilson, et al., 2020). When the PDMP
data indicates potential opioid misuse, clinicians should verify data to rule out errors, conduct a
urine test to confirm misuse, and consider this an opportune time to educate, and discuss
concerns with their patients. Non-opioids alternatives should be considered and discussed with
patients to decrease opioid prescribing and their potential harm. Such an encounter should
enhance patient engagement and education, rather than terminate the provider/client relationship
(Turner et al., 2019). Prescribers should carefully monitor prescribing and dispensing guidelines
and facilitate life-saving addiction interventions.
Providers can use PDMP data to increase reporting of opioid misuse to health insurance
companies, licensing boards, state health departments, law enforcement, and other relevant
agencies (CDC, 2020), to facilitate appropriate interventions. For instance, clients with three or
more visits to several providers in a week should be flagged as doctor shopping and identified as
high risk for opioid misuse. Once PDMP data have been verified and errors ruled out, this
information should be reported to the appropriate authorities for timely interventions. In addition
to facilitating prompt interventions to individuals with OUD, increased reporting of the PDMP
data will raise awareness about the magnitude of the prescription opioid crisis, and stimulate the
assemblage of resources for the development of more treatment centers and skilled care
providers.

INCREASED REPORTING OF PDMP DATA TO ADDRESS OPIOID MISUSE

19

Prescribers must query the Prescription Drug Monitoring Program (PDMP) before
prescribing Schedule II, III, and IV controlled substances and electronically transmit all
prescriptions (McDonald et al., 2019). These strategies will help to monitor the use of eprescribing as an effective tool to control the supply of opioids. Additionally, the PDMP data
must be accessed by licensing boards for possible investigation of misconduct involving
controlled substances. Accessibility of the PDMP data by law enforcement will develop and
warrant investigations but the enforcement of controlled substance laws is the responsibility of
the federal, state, and local sectors (McGinty, et al., 2018).
According to Bonnie et al., (2017) recommendations to improve the use of PDMP data
for surveillance and intervention have resulted in collaborative efforts between the U.S.
Department of Health and Human Services, and state organizations that administer PDMPs. The
plan is to conduct or sponsor research on the utilization of PDMP data to maximize patient
safety. Careful monitoring of these data will focus on policy and other controlled substance
interventions on opioid prescribing, and the impact of prescriber guidelines. Information
obtained will determine health service planning on discrepancies in medications dispensed for
OUD treatment, and for use in clinical care to facilitate clinical decision making and enhance
communication between the patient and provider.
PDMP is currently available in all 50 states. There are discrepancies, however, in its use
among prescribers and individual states. Some of the barriers to the use of the PDMP are lack of
physician training, difficulty with ease of use, and non-transferable data from the electronic
medical records (EMR) (Finnell et al., 2017). According to the CDC, several upgrades are being
made to the PDMP by individual states to improve accessibility and ease of use (CDC, 2020). An
illustration of the PDMP framework is displayed below in figure 1.
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Figure 1. PDMP Framework
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Rationale for Conducting the Review
The rationale for conducting this integrative review is to explore the effectiveness of the
PDMP to address the opioid crisis through its efficient use by prescribers. Prescribers can then
increase the reporting of the opioid misuse data to the appropriate authorities for early
interventions. A thorough scoping and synthesis of published articles relating to the topic of
discussion allowed this writer to extract evidence-based recommendations for interventions such
as increased prescriber education in the use of the PDMP for improved prescribing practices and
reduced patient harm. Furthermore, this writer identified the need for improved practice
strategies such as implementing guidelines on the consistent use of the PDMP among prescribers
and in the different states for safe, and uniformity of care. This writer further identified the need
for enhanced policy development relating to the PDMP, and indicators for further research on its
role as an evidence-based initiative to address opioid misuse.
Purpose
This integrative review intends to explore literature with great significance on the
effectiveness of the PDMP in identifying patients at risk for opioid misuse and increase the
reporting of these data to the appropriate authorities to provide opportunities for timely
intervention (Norwood & Wright, 2016). Lack of physician training, difficulty with ease of use,
untransferable data from the EMR, and inadequate reporting of PDMP data have all been
identified as barriers to the efficient use of the PDMP (Finnell et al., 2017). This indicates the
need for prescribers' education and training on the effective use of the PDMP. Additionally,
through education and enforcement prescribers must comply with opioid prescribing guidelines
for evidence-based practice (Raheemullah et al., 2020). All states should implement standardized
guidelines and direct their PDMPs to proactively analyze data to identify possible misconduct
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and criminal activities, to increase reporting to the appropriate entities (Norwood & Wright,
2016).
The Review Question
The Review question is “How can prescription opioid misuse be addressed through the increased
reporting of prescription drug monitoring program (PDMP) data?” This integrative review
intends to explore literature with great significance to this clinical question.
Formulate Inclusion and Exclusion Criteria
The studies included in this project were restricted to English only, full-text, peer-review
articles published from 2015 to 2020, involving participants ages 18 and older. Studies were
included if the interventions and outcomes related to the PDMP or similar tools, and other
interventions for comparison of outcomes. Studies with a population focus on registered opioid
prescribers, pharmacists, and settings involved in pain management such as the Emergency
Department were included. Studies that also met the inclusion criteria are those relating to
patient and provider education, on opioid misuse, OUD, and safe prescribing for improved
outcomes. Studies on prescription opioid legislation also met the inclusion criteria.
Considering the magnitude of the opioid crisis, the initial search using “opioid abuse”
returned 50, 292 articles, followed by the search term “PDMP” which returned 2,616 articles.
Modifying the search term to “prescription opioid abuse treatment” returned 163 articles. The
PRISMA flow sheet process of identification, screening, eligibility, and inclusion was followed
to select appropriate articles for this integrative review. The articles were reduced to 39 after
duplicates were removed and exclusion criteria applied to studies that focused on illicit drug use,
and prescription opioid use in palliative and hospice care, and psychiatric medicine. After
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stringent scrutiny, 23 (n=23) articles met the criteria for this integrative review because of their
strong relevance to opioid misuse, treatment measures, and the PDMP. Nineteen (n=19) of these
articles are qualitative studies and the remaining four (n=4) are quantitative studies of metaanalysis. Data was arranged under the three main categories including the contributory factors of
the opioid crisis, strategies to address the opioid crisis, and the PDMP, based on each study’s
focus. Additionally, information from other relevant sources including the CDC, the SAMHSA,
and the ANA was obtained for pertinent information on the topic discussed. Included literature is
further displayed in table 1, the inclusion and exclusion table, the PRISMA flow sheet in figure 2
and appendix B, and the Melnyk table of evidence matrix in appendix A., detailing the study
type, samples, authors, and results.
Table 1. Inclusion and Exclusion.
Inclusion Criteria

Exclusion Criteria

English only Peer-reviewed full-text articles
from 2015-2020

Foreign articles

Aged 18 years and older exhibiting signs of
opioid misuse or OUD

Duplicates

Registered opioid prescribers, and pharmacists

Illicit drug use

Pain management settings such as the ED, pain
clinics.

The prescription opioid in palliative and hospice care

Prescription opioid misuse, doctor shopping,
and diversion

Psychiatry medicine

Opioid prevention, interventions, guidelines,
and legislation
PDMP or similar opioid misuse risk tool
Patient and provider education
Safe prescribing practices

Articles published before 2015
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Figure 2. The PRISMA flowsheet diagram
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Conceptual Framework
Cooper’s Theoretical Framework, was the chosen framework for this project, it was
developed in 1988 to classify literature reviews and meta-analysis. This framework helps readers
assess study quality and the relevance to the research question (Hopia et al., 2016). Cooper’s
theoretical framework focuses on practitioners as its intended audience to influence practice
change (Hopia et al., 2016). Practice change can be facilitated through the assessment of
Cooper’s five stages of the framework that guide the review design to improve knowledge and
clinical practice.
The first stage is problem identification, which makes certain that the research question
and purpose are clearly defined (Hopia et al., 2016). The research question being addressed is,
“How can prescription opioid misuse be addressed through the increased reporting of
prescription drug monitoring program (PDMP) data?” The prescription opioid crisis is a known
problem in the U.S. occurring over decades, but more challenging is employing effective
strategies to address this epidemic. The use of PDMP has been identified as having the potential
of being effective in reducing opioid misuse. However, there are mixed reviews about its
effectiveness, due to inconsistencies and inefficiency in its utilization among prescribers and
different states. The integrative review sought to determine the effectiveness of the PDMP in
identifying patients at risk for opioid misuse and increase the reporting of these data to the
appropriate authorities to provide opportunities for intervention (Norwood & Wright, 2016).
The second stage of Cooper’s framework is conducting searches to obtain applicable
information on the topic of discussion. A comprehensive database search was conducted from
renowned sources of only English written articles dated between 2015 to 2020. The searches
returned several studies and using the PRISMA flow sheet, inclusion and exclusion criteria were
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applied to studies of strong relevance to the topic discussed. Table 1 displayed the inclusion and
exclusion criteria. These primary sources were then scoped to gain insight into the effectiveness
of the PDMP in increasing prescribers’ awareness, reduce over-prescription, identify opioid
misuse, and increase reporting of drug-seeking behaviors for prompt interventions (McDonald et
al., 2019). A detailed data search information can be found under the comprehensive data search
strategy heading.
The third stage involved data evaluation during which data obtained were scrutinized for
quality, authenticity, and relevance to the clinical question, and only data of strong relevance
were included in this review. Using the Melnyk table of evidence, data were evaluated ranging
from level I to level VII based on the methodological quality of their design, validity, and
relevance to the topic addressed and application in the clinical setting. Evaluated data was also
displayed on the data analysis table in table 2, the PRISMA flowsheet in figure 2, and Melnyk's
table of evidence levels I through VII in Appendix A, to determine the quality of the literature
and applicability to the topic discussed (Melnyk & Fineout-Overholt, 2019).
Stage four involves data analysis during which included studies were accessed,
examined, and critiqued to explore their relevance in addressing the clinical question. Data
analysis permits the ordering, coding, categorizing, and summarizing of data from the primary
literature source into a comprehensive conclusion about the research topic (Whittemore & Knafl,
2005). In data analysis, the goal is to conduct a detailed and unbiased interpretation of the
primary source through continuous comparisons to convert the extracted data into structured
categories and themes (Whittemore & Knafl, 2005). The chosen themes for this integrative
review are, the contributory factors to the opioid crisis, strategies to address the opioid crisis, and
the prescription drug monitoring program. Studies' outcomes and statistical analysis were also
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examined for applicability in practice. Data were further displayed in the data analysis table in
table 2.
The fifth and final stage is the presentation stage, involving a comprehensive display of
findings in addressing the clinical questions. This stage depicted the prospect of the PDMP and
described the implications for practice, policy, and research, including limitations, and gaps in
practice. Data is further displayed in a table format in the literature matrix in Appendix A, for
comparison and conclusion of findings.
SECTION TWO: COMPREHENSIVE AND SYSTEMATIC SEARCH
Search Organization and Reporting Strategies
Using the Boolean phrase search method, searches were conducted for “prescription
opioids OR narcotics AND pain killers,” prescription opioid abuse OR prescription opioid
misuse,” “opioid addiction OR opioid use disorder,” “opioid epidemic OR opioid crisis,”
“prescription drug monitoring program (PDMP)”, OR “prescription opioid abuse treatment.”
Multiple databases were searched for relevant literature on the topic of discussion using
Ebscohost, Medline, CINAHL Plus, Eric, Health source (nursing academic edition),
Psychological and behavioral sciences search engines. Advanced searches were conducted on
Proquest central, with the help of the librarian for full-text peer-reviewed, English written
articles dated between 2015 to 2020.
Terminology
Boolean Phrase, permits the use of conjunctions such as “AND, OR” when conducting
searches to limit or broaden the search results to relevant articles on the desired topic.
Databases are an electronic collection of orderly stored information that could be easily accessed
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through a computer. Advanced Search facilitates complex searches for relevant sources.
SECTION THREE: MANAGING THE COLLECTED DATA
The collected data underwent stringent scrutiny for inclusion in this project, after a
thorough literature search from renowned databases listed under Search Organization and
Reporting Strategies. The PRISMA flow sheet displayed the process involved in the inclusion
and exclusion criteria and data were further categorized according to the study focus considering
their similarities and differences in addressing the clinical question. A comprehensive display of
data is illustrated in the Melnyk table of evidence in Appendix A, ranging from levels I-VII,
according to the methods, designs, validity, and evidence of the studies to give readers a clear
insight into the topic discussed. Detailed data collection and management can be found under the
inclusion and exclusion criteria heading. Graphic display of data is found in the PRISMA
flowsheet in figure 2, and the data analysis table in table 2.
SECTION FOUR: QUALITY APPRAISAL

Studies by Adewumi et al., (2018), Jefferies (2018), Lagisetty et al., (2017), and Yang et
al., (2018) are level 1 studies based on Melnyk level of evidence. These four studies are systemic
review articles involving randomized control trials (RCTs) that are considered the gold standard
for providing high-quality evidence on diverse aspects on the topic of discussion.
The five level II RCTs included in this integrative review were different studies by Goedel et al.,
(2019), Hawk et al., (2018), Neven et al., (2016), Coffin et al., (2017), and Turner et al., (2019),
because of their methodology, validity, and applicability to safe practices and improved patient
outcomes.
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Two level III articles of quasi-experimental designs by Delcher et al., (2016) and
McDonald et al., (2019) were identified. Both studies were included in this integrative review
because they provide moderate to strong evidence on the PDMP in reducing opioid-related
deaths and increasing the vigilance of prescribers to identify drug risky behaviors in patients. Six
level IV articles included in this scholarly project were studies from Finnell et al., (2017),
Kohlbeck et al., (2018), Raheemullah et al., (2020), Strand et al., (2019), Wilson, et al., (2020)
and Young et al., (2018). The study designs included two pilot studies, one prospective study, and
one mixed study design of surveys, focus groups, and a pre- and post-test interventional study.
These studies revealed some evidence of a practice change in providers' prescription practices
and compliance and identified PDMP as a valuable screening tool to help address opioid misuse.
Information from these studies may stimulate further research on the effectiveness of PDMP to
address opioid misuse through increased reporting of data.
Five level V studies, considered for use in this scholarly project were studies from Kelly
et al., (2016), Lyapustina et al., (2017), McGinty et al., (2018), Norwood & Wright, (2016), and
Rhodes et al., (2019). These studies exhibited diverse research designs ranging from crosssectional studies, the systemic review of literature, mixed study designs, and surveys. Mild to
moderate evidence was revealed on the barriers to PDMP, and factors influencing the opioid
epidemic. The studies also raised awareness about the inconsistencies and gap in practice
involving PDMP utilization for safe prescribing, and implementation laws for consistency.
Relevant information was furnished but further research for strong evidence is necessary for the
future of the PDMP. A study by Rhodes et al., (2019), found no strong evidence of the PDMP in
reducing opioid-related harms but there are indications to guide safe prescribing practices. This
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study can instigate future in-depth research into the capability, utilization, barriers, and
effectiveness of the PDMP in addressing opioid misuse.
The only level VI survey study by Carrico et al., (2018), examined the impact of
incentives and organizational guidelines on opioid prescribing. Despite its low level of evidence,
useful information was furnished to influence safe opioid prescribing policies and practices and
promote professionalism. A detailed description of each article is displayed in a table of evidence
in Appendix A, according to the Melnyk framework (Melnyk & Fineout-Overholt, 2019). This
gives readers an insight into the role of the PDMP in addressing opioid misuse, challenges to its
utilization, and indications for future research. Studies by Bonnie et al., (2017), Neville & Foley,
(2020), and Reinhart et al., (2018), were referenced in this integrative review but were not
inclusive of the 23 studies.
Sources of Bias
The findings reported in this Integrative Review are subject to several limitations. The
studies were restricted to publications from 2015 to 2020, and pertinent data before 2015 may
have been omitted. Only English-written, peer-reviewed articles were selected omitting
international studies that may have provided useful information on the opioid epidemic. The
potential for bias and confounding exists due to the non-randomized design of some included
studies, and other factors that may have influenced the outcomes. For example, the studies by
Delcher et al., (2015), Norwood & Wright, (2016), and Raheemullah et al., (2020) have the
potential for sampling bias because the researches were conducted in single settings; therefore,
the results cannot be generalized. Furthermore, the varying study designs posed challenges in
comparing results, resulting in bias and lack of rigor, making conclusion-drawing vague or
inconclusive. Another limitation was the varying definitions of opioid abuse and misuse among
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studies, and the type of prescription opioids investigated also vary resulting in inconsistency and
study outcomes.
Appraisal Tools (Literature Matrix)
Melnyk's level of evidence matrix was used as a tool to assess the quality of the studies.
The study levels ranged from levels I (strongest evidence) to VII (weakest evidence), according
to the methodological quality of their design, validity, and applicability to the topic of discussion
(Melnyk & Fineout-Overholt, 2019). This display gives readers insight into the role of the PDMP
in addressing opioid misuse, challenges to its utilization, and indications for future research. A
graphic display of data is found in Appendix A. The 27-item PRISMA checklist and a four-phase
flowsheet were used as the tool to evaluate the topic of interest by outlining the flow of
information through the different phases of the systemic literature review, and organized the
number of records identified, guided the inclusion of quality literature and stated the reasons for
exclusions (Tricco et al., 2018). An illustration of the PRISMA flowsheet is in figure 2.
Applicability of Results
In addition to the narrative, results for this review were presented through tables, flow
diagrams and concept maps to give readers a descriptive meaning of the project. The flow
diagrams and concept maps organized data in sequential order by themes or categories for
readers to easily identify the relationships between studies and their relevance to the clinical
question. Data arranged in table format allowed readers to identify the similarities and
differences between the studies and the studies' outcomes and their relevance to the topic of
discussion. The compilation of an integrative review is a very daunting task as it required
exploration and data extraction from different study designs and methods to fully understand the
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topic discussed and its applicability to practice. Additionally, gaps identified in this project can
influence knowledge acquisition, policymaking, and trigger further research.
Reporting Guidelines
The Integrative Review based on the PRISMA guideline was the chosen method for this
scholarly project. The PRISMA guideline promotes quality and transparency in reporting
systemic reviews (Toronto & Remington, 2020). According to Whitmore and Knafl, (2005), an
integrative review specifically summarizes previous empirical or theoretical literature to furnish
a thorough understanding of a specific occurrence or healthcare issue. Integrative reviews can aid
in the development of nursing science, instigate research, influence practice, and policy-making
initiatives. Considered the broadest type of research review methods, integrative reviews
uniquely accommodate the simultaneous inclusion of experimental and non-experimental
research to provide a thorough understanding of the issue at hand which can subsequently impact
evidence-based practice in nursing and healthcare (Whitmore & Knafl, 2005).
An integrative review is considered a review of reviews because of its extensive approach
and capability to capture the complexity of various perspectives, cultivates a comprehensive
understanding of the topic of interest by presenting the science which then leads to theory
development (Hopia et al., 2016). Following the five-step process of an integrative review, the
project emphasized the problem to be studied, completely defined the literature search, evaluated
the data, analyzed the data, and interpreted and presented the conclusion (Hopia et al., 2016).
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SECTION FIVE: DATA ANALYSIS AND SYNTHESIS
Data Analysis Methods
In examining the clinical question, data were analyzed according to Whitmoore and Knafl
(2005), method of coding, categorizing, ordering, and summarizing, to enhance the rigor of the
diverse methodologies of the qualitative studies included. Coding allowed data to be defined,
categorized, analyzed, compared, synthesized, and displayed in a data analysis table in table 2.
The literature was analyzed according to categories and themes such as the contributory factors
to the opioid crisis, strategies to address the opioid crisis, and the prescription drug monitoring
program (PDMP). Relevant literature to each of these categories was diligently scoped and
compared multiple times to obtain important data examining the similarities and differences in
addressing the clinical question.
The contributory factors to the opioid crisis category obtained data from different studies
that highlighted themes such as pain management, over-prescriptions, faulty practices, patient
surveys, and incentives. In examining the relevant literature, Adewumi et al., (2018), explored
factors such as higher doses and unsafe prescribing by practitioners and suggested that
prescribers should discuss safe doses with their clients. The study by Yang et al., (2018), shared
similar sentiments about caution on morphine dosages in adult and pediatric patients and
highlighted opioid misuse risk in prescribing. Lyapustina et al., (2017), explored the impact of
the ED as a contributor to opioid misuse, and reviewed control strategies, whereas Neven et al.,
(2016) focused on strategies to decrease opioid-related ED visits. Carrico et al., (2018), and
Kelly et al., (2016) reviewed the impact of prescribers’ incentives on opioid prescriptions, and
the influence of patient satisfaction scores on prescription practices, respectively.
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Under the category, “Strategies to address the opioid crisis,” themes such as diverse
therapy interventions, education, and legislation were highlighted in the treatment of OUD.
Studies by Lagisetty et al., (2017), examined the benefits of Medication-Assisted Treatment
(MAT), Jefferies (2018) addressed psychotherapy in conjunction with (MAT) as being beneficial
and Coffin et al., (2017) discussed the therapeutics of behavioral interventions. Goedel et al.,
(2019), stressed the benefits of peer support, and Turner et al., (2019) emphasized the importance
of patient education. Other studies by Raheemullah et al., (2020), and Young et al., (2018),
discussed the improvement of opioid prescribing practices among prescribers through education
and training. Strand et al., (2019) and McGinty et al., (2018), focused on the implementation of
opioid misuse risk tool, and the enforcement of consistent and safe opioid prescribing laws.
In the final category of data analysis, themes such as national database, opioid misuse
risk, prescribers’ attitudes, and safe prescribing were notable. Increase reporting of data from the
prescription drug monitoring program (PDMP) to address opioid misuse, is the focus of the
clinical question. Literature under this theme explored the benefits and disadvantages of the
PDMP, the barrier to its use, prescribers' attitude towards its use, and the future of the PDMP in
addressing opioid misuse. Studies by Finnell et al., (2017), Hawk et al., (2018), Kohlbeck et al.,
(2018), McDonald et al., (2019), Norwood & Wright, (2016), focused on increasing prescribers'
knowledge and the efficient use of the PDMP. Delcher at al., (2016), and Wilson et al., (2019),
assessed the impact of PDMP and similar screening tools on opioid misuse. Rhodes et al.,
(2019), found no strong evidence that the PDMP reduced opioid-related harms, but cautioned
physicians’ opioid prescribing habits.
This literature was critically analyzed and constantly compared to identify similarities
and differences, taking into account the study methodologies, purpose, sample sizes, risk of bias,
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and other variables that impacted their validity in answering the clinical question. Table 2.
displays a summary of the data analysis. Analysis of data is also found in the five stages of
Cooper’s theoretical framework of problem identification, literature search, data evaluation, data
analysis, and presentation. A comparison chart is found under each subcategory in the synthesis
of results.
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Table 2. Data Analysis

Categories

Themes

Supporting Articles

Contributory

Pain management

Adewumi et al., (2018), Carrico et al., (2018),

factors to the

Over-prescription

Kelly et al., (2016), Lyapustina et al., (2017).

opioid crisis

Faulty practices

4

Patient surveys, and
incentives

Strategies to

Diverse therapy

Goedel et al., (2019), Jefferies, S. (2018), Lagisetty, et

address the opioid

interventions,

al., (2017), McGinty et al., (2018), Coffin, et al.,

crisis

Education,

(2017), Raheemullah et al., (2020), Strand et al.,

Legislation

(2019), Turner et al., (2019), Yang et al., (2018),

10

Young et al., (2018).
The Prescription

National database

Delcher et al., (2015), Finnell et al., (2017), Hawk et

drug monitoring

Opioid misuse risks

al., (2018), Kohlbeck et al., (2018),

program (PDMP)

Prescribers attitudes

McDonald et al., (2019), Neven et al., (2016),

Safe prescribing

Norwood & Wright, (2016), Rhodes et al., (2019),

Barriers

Wilson, et al., (2020).

9

INCREASED REPORTING OF PDMP DATA TO ADDRESS OPIOID MISUSE

37

Synthesis of Results
In answering the clinical question, three major categories have been analyzed including,
Contributory factors to the opioid crisis, Strategies to address the opioid crisis, and the
prescription drug monitoring program (PDMP).
The Contributory Factors to the Opioid Crisis
Four studies in this integrative review have identified several factors that contributed to
the opioid crisis. Through a systematic review and meta-analysis of RCTs, Adewumi et al.,
(2018) examined seven studies out of 1332 to associate an increased risk of unintended opioid
overdose with 20-50 morphine milligram equivalents (MME)/day, and an increased risk of
fatalities with higher doses of 50 MME/day or higher. The study recommended that providers
should discuss safe opioid dosages with their patients when prescribing. Findings from this study
partially addressed the clinical question, in promoting efficiency in opioid prescribing and
patient safety. “The study quality was assessed using the Newcastle–Ottawa Scale (NOS), and a
random-effect model was used to summarize the results using relative risk (greater than
50 MME/day, p < 0.001; greater than 100 MME/day: p < 0.001;)” (Adewumi et al., 2018, p.
105).
In a systemic review of peer-reviewed articles, Lyapustina et al., (2017) conducted a
similar study on opioid prescriptions but unlike Adewumi et al., (2018) the study focused on the
ED as a contributor to prescription opioid misuse and diversion. “The results revealed that
approximately 10% of the prescription for opioids issued in the ED are indicative of
inappropriate prescribing, and an estimated 42% of opioids are at increased risk of misuse, and
10% of diverted opioids originated from an ED prescription. Importantly, 1.8% of prescription
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opioid-related deaths are linked to the ED” Lyapustina et al., (2017). Further research is needed
but based on current literature an urgent need for interventions in the ED is required to reduce
overprescribing, prescription opioid misuse, and diversion. This study provided strong evidence
on increasing awareness among prescribers on safe opioid prescribing and adherence to safe
prescribing guidelines.
Comparing the studies of Adewunmi et al., (2018) and Lyapustina et al., (2017), both
focus on the safety of opioid prescribing practices. Adewunmi et al., (2018), was specific to the
prescribing practices of morphine doses, whereas, Lyapustina et al., (2017) was more generalized
with concerns about the ED being a contributor to prescription opioid misuse, diversion, and
deaths, particularly with drugs such as oxycodone and hydrocodone. These findings can serve as
educational resources to caution against opioid over-prescriptions.
A survey study on 1404 family physicians in a Colorado practice was conducted by
Carrico et al., (2018) and a descriptive study on 141 ED physicians by Kelly et al., (2016) gave
insights into some of the pressure experienced by providers through incentives or by economic or
regulatory factors imposed on them that influence their prescribing practices. Results from
Carrico et al., (2018) “revealed that thirty-six percent (n = 14) of physicians who received
incentives by patient satisfaction reported a slight influence on their opioid prescribing practices
compared to 12% (n = 8) of physicians who did not receive incentives (P = .004). Pearson's χ2
tests with 2-sided asymptotic significance were used to make comparisons” (Carrico et al.,
2018). This study provided important information, for the review of proper guidelines on
prescribers’ incentives and their influence on prescribing standards, and the impact of patient
satisfaction scores on prescribers’ integrity and prescribing practices, and administrative
guidelines.
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Kelly et al., (2016), revealed that 40% of responding participants or their co-workers
have been formally disciplined for failure to prescribe opioids. The majority of respondents felt
pressured to write prescriptions to avoid administrative interrogations from dissatisfied patients
regarding inadequate pain management. Failure to prescribe opioids in such circumstances can
hinder reimbursement, and negatively impact Joint Commission scores. Additionally,
participants reported a lack of clarity from all governing levels regarding the management
protocol for patients suspected of “doctor shopping.” Further research is needed to identify
appropriate interventions to bridge the gaps identified in this study in training, regulation, and
administrative healthcare practices for the appropriate management of patients with “drugseeking” behaviors. Chi-square statistics were used to determine the differences between
participants, P < 0.05 (Kelly et al., 2016). Useful information was garnered from this study to
increase knowledge on safe prescribing practices among providers. Both studies raised important
points on the influence of physician incentives and patient satisfaction scores, which warrants
investigation of these practices to implement proper safety and prescribing guidelines.
Studies in this category did not fully answer the clinical question, they mostly focused on
the prescribing practices which are important components for safe practices but the increased
reporting of the opioid misuse data obtained from the PDMP is the focus of the clinical question.
A visual summary of results is displayed in a chart format in figure 3. Further investigation is
therefore warranted into the efficient use of the PDMP in reporting data to address the opioid
crisis.
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Figure 3. Contributory Factors to the Opioid Crisis

The concept of pain as the fifth vital sign triggered increased
opioid prescriptions, with less focus on addictive effects
Kelly et al., (2016)

Cautioned against higher doses of opioid prescriptions, and
recommended prescribers to discuss this issue with
patients
Adewunmi et al., (2018)
Addressed the issue of the ED as contributor to opioid
misuse through increased prescribing
Lyapustina et al., (2017)

Contributory Factors to
the Opioid Crisis

Highlighted the influence of prescribers' incentives on
opioid prescriptions

Emphasized the impact of patient satisfaction survey on
opioid prescribing

Carrico et al., (2018)

Kelly et al., (2016).
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Strategies to address the opioid crisis
Addressing the opioid crisis involved collaborative efforts and diverse strategies to
answer the research question. Studies by Jefferies, (2018), Lagisetty et al., (2017) and Coffin et
al., (2017) used systematic review and meta-analysis of RCTs, and a pilot study of RCTs to
explore the effectiveness of diverse therapies to address opioid use disorder (OUD) in the health
care environment. In a systematic review and meta-analysis of thirty-five interventions including
ten RCTs and 25 quasi-experiments, Lagisetty et al., (2017), further recommended MedicationAssisted Treatment (MAT) interventions to identify programs and processes associated with
improved patient outcomes, to guide future policy implementation in the primary care settings.
Comparable to Lagisetty et al., (2018), conducting a combination of fifteen systematic reviews
and meta-analyses of RCTs, Jefferies (2018) emphasized the use of psychotherapy in
conjunction with MAT as an effective intervention for opioid use disorder (OUD).
Similarly, Coffin et al., (2017) conducted a pilot single-blinded RCT on 63 participants
ages 18-65 with a history of OUD and overdose. The pilot study further examined behavioral
interventions to augment naloxone distribution to reduce opioid overdose. These studies provide
valid information on diverse therapies of MAT, psychotherapy, and behavioral interventions in
the treatment of opioid use disorder. However, varying interventions used by Jefferies (2018)
affected the strength of the study outcomes. Likewise, the potential for bias and confounding
exists with the study by Lagisetty et al., (2017) since all of the studies were not randomized
designs. Participants in the study by Coffin et al., (2017) were less likely to experience an
overdose, 87% of participants were pleased with the amount of help they received as part of the
study.
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Compared to Jefferies, (2018) and Coffin et al., (2017) regarding non-pharmacological
interventions, Goedel et al., (2019) used a parallel design to study 650 high-risk adult patients for
opioid overdose problems presenting to the ED. The participants were randomly assigned 1:1 to
receive a behavioral intervention from either a certified peer recovery support specialist or a
licensed clinical social worker (LCSW) to reduce the frequency of their ED visits, and recurrent
opioid overdose. Findings from this study have the potential to create evidence for peer recovery
support services as an effective intervention for fatal and non-fatal opioid abuse which can aid in
addressing the impact of opioid misuse. This study also facilitated unlimited access to datasharing between key entities such as hospitals, behavioral healthcare facilities, and researchers
on overdose-related morbidity and mortality.
Turner et al., (2019), shared a similar notion with Goedel et al., (2019) to address opioid
misuse through a government-led, patient education program using an RCT design. This fostered
communication between patients and providers about their opioid use and explored alternative
pain treatments. This also led to a reduction in inappropriate prescriptions of sedative-hypnotic
and non-steroidal anti-inflammatory drugs (NSAID). Results from this trial served as a guide for
future use in the community and can be applied to current practice to promote patient education.
Some limitations include missing information on the storage of certain medications. Possible
selection bias due to the faulty participant identification process. Codeine and tramadol were not
included as opioids and can be considered safe, which can potentially lead to over-prescription
and overdose. “The T-test compared the means of normally distributed variables and a p-value of
< 0.05 considered statistically significant” (Turner et al., 2019).
Using a pre-and post-test interventional study design, Raheemullah et al., (2020)
conducted an educational program to assess opioid-prescribing practices and pain management
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skills of residents without faculty presence. An improvement in residents’ confidence in
detecting and managing addiction and improved prescribing practices and adherence to CDC
recommendations were observed. Limitations of this study involved only one university setting,
and the year of the residents was not disclosed. Therefore, outcomes, cannot be generalized,
which required similar studies to be conducted at other universities for comparison. In answering
the clinical question, providers’ education and efficiency are crucial to guide safe practices,
identify misuse, and initiate timely interventions.
Studies by Strand et al., (2019), and Yang et al., (2018) examined opioid misuse risk and
assessed the effectiveness and side effects of opioids. In a pilot study, Strand et al., (2019),
examined the implementation and evaluation of an opioid misuse risk prevention toolkit among
community pharmacists to screen for opioid misuse behavior in patients receiving opioid
prescriptions. Results revealed a strong preference for this tool by the community pharmacists to
facilitate education and early interventions. Twenty-six percent of individuals receiving opioid
prescriptions showed some risk of misuse and 30% were at risk of an accidental overdose.
Selection bias is possible due to the convenience sampling of patient-participants. This study has
the potential for both recall bias and response bias due to the self-reported tool, and the
furnishing of inaccurate responses from patients. Improving prescribers’ education can result in
improved outcomes.
In a systemic review of RCTs, Yang et al., (2018) explored the effectiveness and side
effects of opioids both in adult and pediatric burn patients, to guide practitioners in pain
management. Results revealed that topical morphine application alleviates burn-related pain and
anxiety, and opioid-related side effects also decreased over time. Limited sample size hindered
evidence for the beneficial effect of opioids, and only one drug was studied. Further RCTs with
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improved sample sizes are needed to strengthen this study. The Cochrane risk-of-bias
method was used to assess the overall quality of the included studies. The study lacked statistical
methods for data analysis, therefore, all results were narratively analyzed. This study can caution
prescribers on the potential side effects of morphine and possibly other opioids despite their
benefits in alleviating pain and anxiety. Therefore, prescribers’ education on the safety of opioid
prescribing is important.
As part of a quality improvement project, a pilot study designed by Young et al., (2018)
was conducted to limit opioid prescribing in urgent care settings, that manage acute pain. Results
showed an immediate decline in the average number of opioid prescriptions written per provider
per week during the study. A Paired t-test was used to assess the statistical significance of
changes in opioid prescribing, (P < 0.05). A disadvantage of this study is that prescribers can
resume unsafe prescribing practices at the end of the study. Most important, however, is that
provider awareness, education, and safe prescribing guidelines are essential.
Regarding safe prescribing guidelines, McGinty et al., (2018) conducted a mixedmethods study to evaluate the implementation, enforcement, and outcomes of the U.S. laws on
restricting high-risk opioid prescribing and non-opioid treatments for chronic non-cancer pain.
Limitations included inconsistencies in law implementation and enforcement among states which
led to diverse outcomes. Data inaccuracy from IQVIA resulted in data collection bias, and there
was no differentiation between pain treatments as clinical or non-clinical. Strict implementation
and adherence to state laws are required, warranting further research. Information obtained from
this study can help address the inconsistencies in opioid practices among providers and states.
The studies under this category examined various strategies employed to address the opioid
crisis, some with improved outcomes, and others with inconsistencies. These studies shared
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similar notions as the clinical question to address opioid misuse, however, none were specific on
reporting PDMP data to address opioid misuse. This indicated a need for further studies on
prescribers' education on the increased reporting of PDMP data. A graphic summary of the
results is displayed in figure 4.
Figure 4. Strategies to Address the Prescription Opioid Crisis
Diverse Ther

Medication assisted Treatment (MAT)
Lagisetty et al., (2017)
Medication Assisted Treatment (MAT) & Psychotherapy
Jefferies (2018), Coffin et al., (2017)

Educated prescribers on safe opioid prescribing practices
Raheemullah et al., (2020)
Young et al., (2018)

Behavioral Interventions
Goedel et al., (2019)
Patient education
Turner et al., (2019)

Strategies to Address the
Opioid Crisis
Utilized Opioid Misuse risk tool and pain management
strategy to identify at-risk patients
Strand et al., (2019)
Yang et al., (2018)

Recommends opioid Prescribing Implementation Laws to
mandate consistent and safe prescribing practices
McGinty, et al., (2018)
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The Prescription Drug Monitoring Program (PDMP)
Efforts to address the opioid crisis included the implementation of the PDMP for safe
prescribing and reduction in patient harm. The focus of this project is to address the clinical
question on the efficient use of the PDMP to increase the reporting of opioid misuse. Nine
articles were identified to explore the effectiveness of PDMP in addressing opioid misuse. A
quasi-experiment conducted by Delcher et al., (2015) on 120 monthly observations and the
number of oxycodone-related deaths indicated that PDMP (p=0.008) had a significant impact on
decreasing oxycodone-related deaths (p=0.002) after it was implemented system-wide, in the
state of Florida. This is the first study to indicate that a state PDMP is effective in reducing
oxycodone-caused mortality. The test used for oxycodone-related mortality was the ARIMA
(0,1,1).
Limitations of this study are, it was only conducted in the state of Florida and the study
outcome might not apply to other states. Furthermore, possible changes to drug treatment access
were not evaluated which might have resulted in the oxycodone decline at the time of the study.
Additionally, there was a possible misclassification of the primary cause of death involving
multiple drugs. Extending this study to other states is recommended for detailed drug-specific
analyses to determine the effectiveness of PDMPs (Delcher et al., 2015). Despite this is an
isolated study, the result showed a prospective future for the PDMP which addressed the clinical
question of using the PDMP to help address opioid misuse.
Using a pre- and post-test interventional design, Finnell et al., (2017), emphasized the
role of continuing medical education for clinicians, to increase enrollment in prescription drug
monitoring programs. There was a significant increase in clinicians’ use of the PDMP after
education (P = 0.06) and a great improvement in clinician knowledge in identifying addiction
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characteristics that are indicative of opioid diversion or abuse. The use of PDMP (P < 0.001) was
also acknowledged as an effective tool. Limitations of this study revealed that increased clinician
knowledge and the likelihood of using the PDMP did not improve clinicians' enrollment in the
state’s PDMPs. Despite the outlook for PDMP is promising, additional research is needed on
barriers to its enrollment and utilization (Finnell et al., 2017). This study addressed the clinical
question regarding increasing providers’ knowledge and the efficient use of the PDMP to
identify opioid misuse behavior among patients.
A similar multi-step study consisting of a survey, a focus group, and a pre-and post-test
educational intervention study, conducted by Kohlbeck et al., (2018), shared similar interest as
Finnell et al., (2017), in addressing clinician knowledge, attitudes, and behavior around opioid
prescribing. The result revealed an increase in providers’ knowledge about the PDMP, which
subsequently fostered a practice change (P < 0.05). However, there is a possible recall and
response bias due to the self-reporting of surveys. Both studies highlighted the importance of
education in changing practice behaviors and facilitated the efficient use of PDMP.
Hawk et al., (2018), McDonald et al., (2019), Norwood & Wright, (2016), and Rhodes et
al., (2019), focused their studies on the consistent and effective use of the PDMP to increase
providers’ awareness on opioid misuse behavior and adopt consistent use of the PDMP to
prevent further patient harm. Hawk et al., (2018), conducted an RCT to evaluate a previous year
PDMP opioid prescriptions and self-reported opioid use among an ED patient with OUD. Results
from the state’s PDMP data indicated that 36% of patients had at least one opioid prescribed, and
even patients with non-medical prescription opioid were able to obtain some amount of PDMP
opioid prescriptions. Clear guidelines are lacking on how the PDMP data should be interpreted
for individual patients. This then warrants the need for evidence‐based guidelines on the
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integration of PDMP data into clinical practice and decision making as PDMP utilization
mandates become standardized (Hawk et al., 2018). This study revealed that PDMP data was
used to identify questionable prescribing practices to address opioid misuse, to adequately
answer the clinical question, these data must be reported to the proper authorities for further
interventions. Further research is therefore required on the efficient and consistent use of the
PDMP in increased data reporting.
McDonald et al., (2019) used a controlled trial to test the effectiveness of unsolicited
reporting by a PDMP to lessen the inappropriate acquisition of opioids. Results indicated a 13 %
decrease in the likelihood of continued prescribing practices among providers who received
unsolicited notices than providers who were not notified. An ordinary least squares regression
was used to estimate notification effects. The limitation of this study is an inaccurate method of
matching the prescriptions to individuals, that possibly resulted in bias, and confounded the true
measure of the prescription activities. Effective use of the PDMP would involve requiring all
physicians and other prescribers to query PDMP data before prescribing controlled drugs.
Norwood & Wright, (2016) used a cross-sectional study design to promote the consistent
use of PDMP, by identifying barriers to its use, and increased awareness about prescription drug
abuse. Multiple logistic regressions were used to examine the relationship between using
INSPECT (a version of PDMP) and the provider's level of concern with prescription opioid
abuse in the community. The results revealed that outpatient pharmacists were ten times more
likely to report using the INSPECT if they were overly concerned with prescription drug abuse
as opposed to those who were not. They were also 18 times more likely to frequently use
INSPECT than those who were not. The study recommended that healthcare professionals
should explore ways to remove barriers to using INSPECT and raise awareness within the
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pharmacy community about prescription drug abuse to promote consistent use of the PDMP
(Norwood & Wright, 2016). Limitations to this study are, it was conducted in only one state,
therefore generalizations cannot be made. There is a need for similar studies to be conducted in
multiple settings to compare outcomes. Furthermore, low survey response rates can result in a
possible bias. The consistent use of the PDMP will lead to improved outcomes in addressing the
opioid crisis per the clinical question.
Neven et al., (2016) and Wilson, et al., (2020) explored tools such as the care
coordination information system, Current Opioid Misuse Measure (COMM), and PDMP to
identify opioid misuse and diversion, decrease unnecessary ED visits, and controlled substance
prescriptions. Neven et al., (2019) conducted an RCT of a citywide emergency department care
coordination program to reduce prescription opioid-related Emergency Department Visits. The
study was effective in reducing ED visits and controlled substance prescriptions. Chi-squared
and t-tests were used to assess the success of the randomization procedure. A decrease in ED
visit was noted among all study participants during the 12-month study observation duration by
approximately 4% per month. This care coordination information system should be extended to
other hospitals to allow appropriate treatment of patients suspected of “doctor shopping” to
provide them with follow-up care coordination for the required treatment. Limitations of this
study are patients may stop coming to the ED and obtain prescriptions elsewhere or explore other
means of obtaining opioids. Additionally, only one state was studied which may not be a
representation of other states. Similar studies should be conducted in other areas to compare
outcomes. This study partially addressed the clinical question concerning the use of the PDMP to
identify opioid misuse to initiate appropriate interventions.
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In a prospective study, Wilson et al., (2020), compared the PDMP and the Current Opioid
Misuse Measure (COMM), a commonly recommended screening tool to detect drug-aberrant
behaviors in opioid patients in the ED. The results revealed that both PDMP and the COMM did
not improve the detection of drug-aberrant behaviors. The PDMP, however, omitted many
patients with documented drug-risky behaviors in the electronic medical record (EMR),
therefore, it should not be used independently to determine the appropriateness of a particular
opioid prescription. This study revealed some of the barriers to the PDMP such as the omission
of important patient data. This can trigger strategies for improvement through further research
and continuous development of the PDMP.
Rhodes et al., (2019) conducted a systematic review on 22 studies (49 PDMPs), and the
results showed no evidence to strongly support the overall effectiveness of PDMPs in reducing
opioid-related consequences and harms. However, the PDMP acted as a reminder to physicians
to use caution when prescribing opioids. Using the PDMP as a precautionary measure for opioid
prescriptions is encouraging. The clinical question, however, is not fully addressed but provided
useful information to trigger further research in the improvement and effectiveness of the PDMP
through increased reporting of data.
The studies in this category did not adequately answer the clinical questions, but most of
them acknowledged the PDMP as promising in addressing opioid misuse and guiding safe
practice. Some studies identified barriers to the PDMP; others failed to establish a correlation
between the PDMP and reduced opioid-related outcomes. These mixed results can facilitate
future research on improving the PDMP and increase prescribers’ knowledge in reporting of
PDMP data. Figure 5 displays a graphic summary of the results.
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Figure 5. The Prescription Drug Monitoring Program (PDMP).
I
Increase Prescribers' Knowledge and Efficienct use of
PDMP
Finnell et al., (2017,
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Ethical Considerations
No human subject participants were involved since the project design was an integrative
review of the literature; obtaining consent was, therefore, not required. The Institutional Review
Board’s (IRB) approval was not needed but under the direction of the project chair, research and
ethical guidelines were followed according to the Liberty University protocol. Copies of the
Collaborative Institutional Training Initiative (CITI) Certificates and the exemption email from
the IRB are provided in the appendix to validate competency in the integrative review process.
TIMELINE
Due to the current status of the COVID-19 pandemic, the original scholarly project
design was changed from a pre-and post-test educational intervention to an integrative review.
Proposal sections one through three was submitted on April 28, 2020, for the program chair’s
review. On May 1, 2020, the project chair and this writer discussed the proposal via telephone,
and required documents were emailed to this writer to continue working on the proposal
development. Another submission was made to the program chair on May 2, 2020, and feedback
was received requiring modifications. A modified version of the proposal was submitted on May
22, 2020, and feedback was received from the chair on May 26, 2020, requiring minor editing,
with a recommendation to proceed with IRB application. The IRB application was submitted on
May 27, 2020, and a response was received on May 29, 2020, stating that the scholarly project
required no IRB approval since no human subjects are involved in the research.
A signed acceptance of the proposal for the Integrative Review was received on June 2,
2020, via email from the project chair. The first draft of the scholarly project was submitted to
the project chair on June 10, 2020. Feedback from the project chair was received on June 12,
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2020, recommending some modifications to the scholarly project, and resources provided to
guide project completion. August 3, 2020, a modified version of the scholarly project was
submitted to the project chair, and feedback was received on August 6, 2020, to proceed to
project defense after editing from an editor. The final edited manuscript was submitted to the
project chair on August 17, with a proposed defense date of August 24.
SECTION SIX: DISCUSSION
This integrated review of 23 diverse research studies contributed to the growing body of
synthesis focused on prescription opioids as a public health crisis and the various strategies to
combat it, including the PDMP. The information obtained could be considered for evidencebased implementation because of its relevance to the opioid crisis and management strategy.
Additionally, an insight into opioid abuse and its management was explored which can foster
behavioral changes in providers’ prescribing practices, patients’ drug-seeking behaviors, and
compliance with opioid abuse therapies.
Multiple contributory factors to the opioid crisis have been identified, therefore effective
strategies should be employed to address this epidemic. Information retrieved from the literature
review indicated a significant need in providers’ adherence to safe opioid prescribing, and
knowledge gaps in the effective utilization of the PDMP to increase reporting of opioid misuse to
the appropriate authorities. The PDMP is believed to have a promising future, at the state level as
an interventional tool to improve opioid prescribing, improve clinical practice, decrease the use
of multiple providers, and protect the at-risk patient from harm (CDC, 2020). However, mixed
reviews about the PDMP still exist on its effectiveness to address the opioid crisis, which
warrants further research (Rhodes et al., 2019). Furthermore, policy changes must be
implemented to ensure that all states work under uniform opioid prescribing guidelines for safe
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and consistent care (McGinty, et al., 2018). This study also contributed to the existing literature
on the facilitators and barriers of the PDMP. Information obtained from this project can provide
educational resources to educate providers on opioid prescribing practices, patient education,
alternative pain therapies, and increased awareness about the PDMP to resolve barriers to its use.
Before conducting this integrative review, this author had the privilege to interview an
emergency department (ED) physician and a walk-in clinic physician, and two Advanced
Practice Registered Nurses (APRNs). Each of these individuals acknowledged using the PDMP
to verify narcotic prescriptions but none of them had reported its data to the appropriate
authorities for further interventions. Their responses to suspected opioid-seeking patients are
denial of prescription refills and immediate dismissal from the clinical environment, and the
involvement of law enforcement if patients became agitated. Subsequently, there is a significant
need to increase prescribers' knowledge on the effective utilization of the PDMP to guide safe
prescribing and reduce patient harm (Finnell et al., (2017), through increased reporting. Barriers
to PDMP such as ease of use, untransferable data from the EMR should be addressed to facilitate
interoperability.
Implications for Practice/ Future Work
The population of focus in this integrative review is opioid prescribers and dispensers,
which may include physicians, nurse practitioners, physician assistants, midwives, and all other
licensed opioid prescribers, and pharmacists. In their daily practice, providers care for patients
with diverse healthcare needs, with the most common problem being pain management. The
efficient use of the PDMP will promote safe opioid prescribing practices and increase the
reporting of at-risk patients for prompt interventions. Some providers acknowledged that they
have knowledge about the PDMP but have not been trained on its proper usage (Radomski et al.,
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2018). Prescribers must be educated on the efficient use of the PDMP to guide safe prescription
practices.
The knowledge obtained from this integrative review will benefit prescribers in settings
such as the emergency departments (ED), which sees an influx of diverse patients including
those on prescription opioids. A study conducted by Lyapustina et al., (2017) identified the ED
as a contributory factor to opioid misuse and abuse, therefore, studies from this integrative
review will be valuable in educating ED prescribers on safe opioid prescription to influence
practice change. Other areas of practice such as urgent care, pain clinics, walk-in clinics, health
departments, and doctors’ offices, and pharmacies will also benefit from information relating to
the topic of discussion to increase knowledge and efficient use of the PDMP to guide safe opioid
prescribing and dispensing practices.
Results from this integrative review may trigger the development of resources such as the
availability of treatment facilities and trained skilled providers to care for patients with OUD.
Prompt identification of at-risk patients for opioid abuse should facilitate therapeutic
communication between provider and client, and not terminate the provider-client relationship.
Increased patient education about the addictive effects of opioids can lead to the exploration of
alternative therapies. Early identification and increased reporting of opioid misuse will facilitate
prompt interventions to prevent overdose and untimely deaths. Data from this review can serve
as a reminder to prescribers on their ethical and moral duty to do no harm and reinforce
adherence to the CDC opioid prescribing guidelines. Furthermore, uniformity of opioid
prescriptions and utilization of PDMP across all states will maintain consistency in safe practice
and reduce “doctor shopping” and other forms of opioid diversion, addiction, and untimely
deaths.
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Dissemination
In determining the best way to disseminate the information, the purpose of the project
must be analyzed, the target audience considered, and the expected outcomes reviewed.
Information can also be disseminated through the submission of an abstract for a poster
presentation, in-services presentation either at the organizational or state level and national
conferences. Education is essential to increase knowledge of PDMP, therefore prescribers should
have access to studies through publications. Project publications are important ways to share
information because they can be easily implemented in the clinical setting where there are
frequent encounters between care providers and patients with OUD, to improve patients’
outcomes. A major barrier to implementation is cost and the attitudes of practitioners to accept
and comply with new practice guidelines, however, through effective collaboration of all
stakeholders a favorable decision can be made to influence practice for improved outcomes.
DNP Essentials
DNP I: Scientific Underpinnings for Practice (AACN, 2006).
The five stages of Cooper's theoretical framework guided the integrative review design to
help assess study quality and provide a framework for the relevance of the efficient use of the
prescription drug monitoring program (PDMP) by prescribers to increase reporting of opioid
misuse, in addressing the opioid crisis. Cooper’s theoretical framework focuses on practitioners
as its intended audience to influence practice change (Hopia et al., 2016). Relating Cooper’s
framework to the topic of discussion, it is evident that there is a dire need for practice change
according to the review of the literature. Practice change can be facilitated through the educating
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of prescribers on the effectiveness of the PDMP to bridge the knowledge gap and guide safe
prescribing practices.
DNP II: Organizational and System Leadership for Quality Improvement and System Thinking
(AACN, 2006).
The information obtained from this literature review has given this writer an insight into
the magnitude of the opioid crisis, and the complex needs of clients affected by opioid misuse,
addiction, and overdose. This also encouraged this writer to assess her leadership qualities to
influence safe opioid prescribing in the clinical setting. As an advanced practitioner, this writer
hopes to use this information to influence the development of clinical practice guidelines, outline
evidence-based interventions, and evaluate practice outcomes on prescription opioids.
DNP Essential III: Clinical Scholarship and Analytical Methods for Evidence-Based Practice
(AACN, 2006).
Using the PRISMA model a review of relevant literature was conducted for the
implementation of best practices on the care of clients with prescription opioid misuse. However,
results indicated knowledge gaps in the efficient use of the PDMP, warranting a need for
providers’ education on the PDMP as best practice for addressing opioid misuse, and evaluating
performance outcomes. Further research is therefore warranted for concrete evidence on the use
of the PDMP as an evidence-based tool for safe practice.
DNP Essential IV: Information Systems/Technology and Patient Care Technology for the
Improvement and Transformation of Health Care (AACN, 2006)
Information technology facilitates the provision of safe, efficient, patient-centered care.
Utilizing information technology such as the PDMP as screening tools to identify patients who
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are at risk for opioid misuse, can promote increase reporting of data to initiate timely
interventions. This can also help address the prescription opioid crisis by decreasing misuse,
abuse, and deaths. Prescribers need to be well vast and registered to efficiently use the PDMP for
safe prescribing practices and reduced patient harm.
DNP Essential V: Health Care Policy for Advocacy in Health Care (AACN, 2006).
Based on the literature review, a significant need for opioid prescription policy change is
apparent at the organizational and state levels due to inconsistencies in prescribing practices by
individuals and states. knowledge acquisition and involvement in policy and advocacy in
prescription opioid guidelines are crucial to facilitate effective change. Furthermore, adherence
to opioid prescribing guidelines is of great importance.
DNP Essential VI: Inter-Professional Collaboration for Improving Patient and Population Health
Outcomes (AACN, 2006).
Some important information encountered in writing this integrative review is the lack of
treatment facilities for opioid abuse victims and the unavailability of skilled practitioners which
magnified the opioid crisis. Collaboration with other healthcare members to facilitate early
screening for opioid misuse and easy access to treatment centers and related resources for
individuals with opioid use disorder (OUD) is imperative. The availability of treatment centers
and trained skilled providers will promote quality care and improve outcomes for clients with
OUD.
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DNP Essential VII: Clinical Prevention and Population Health for Improving the Nation’s Health
(AACN, 2006).
The opioid crisis is a public health issue and several contributory factors have been
identified. Studies from the literature review identified several strategies for prevention and
improved outcomes. However, there is more work to be done in addressing opioid misuse
through developing, implementing, and evaluating strategies to improve population health
through safe prescribing practices. The most important is the education of patients, communities,
and prescribers on the potential dangers of opioid prescription misuse to increase awareness,
guide practice, and improve outcomes.
DNP Essential VIII: Advanced Nursing Practice (AACN, 2006).
The Doctor of Nursing Practitioner has the ethical duty of showing compassion, and
exploring resources to provide quality care for individuals struggling with OUD. As a subject
matter expert and leader, the DNP will influence clinical decision making for quality patient care
and improved outcomes, through comprehensive needs assessment for opioid misuse victims.
Collaboration, advocacy, and policy development are dire in addressing the opioid crisis.
Conclusion
Despite various strategies had been initiated to address the opioid epidemic, it remains a
problem. The use of the PDMP can be an essential tool to identify at-risk prescription opioid
misuse, encourage providers' versatility in using this database, and increase reporting of clients
exhibiting opioid misuse behaviors. This will facilitate prompt intervention based on the client's
level of risk. The inefficient use of PDMP among providers and its inconsistent guidelines
among states resulted in mixed evidence which warrants further research. Despite the mixed
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evidence, PDMP has shown some improvements in identifying opioid misuse behaviors, which
subsequently reduces opioid over-prescription.
Increased prescribers’ education and consistent use of the PDMP is fundamental to
eliminate the gaps in PDMP use across the country to guide safe prescribing practices (Young et
al., 2017). Findings from this Integrative Review highlighted the multiple impacts of the
prescription opioid crisis on healthcare, society, and the economy. Future research into the use of
PDMP as a tool for best practice to reduce opioid misuse is warranted. Additionally, legislation
regarding prescription opioids should be reviewed for consistent and mandatory implementation
to address this opioid epidemic.
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Appendix A
Table 1: Evidence Table
Name: Claudia Georgestone
Review Question: “How can prescription opioid misuse be addressed through the increased reporting of prescription drug monitoring
program (PDMP) data? This integrative review intends to explore literature with great significance to the topic of discussion.”

Article Title,
Author, etc.
(Current APA
Format)

Example, A. (2015)
Title, etc. per Current
APA

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

To identify the
need for
technology to
prevent falls

A convenience
sample of 44
nurses in an acute
care hospital

Methods

A nonexperimental,
descriptive
survey

Study Results

Findings indicate that
fall rates decreased by
2% with the
introduction of
technology into the care
setting

Level of
Evidence
(Use
Melnyk
Framewo
rk)

Level 6:
descriptiv
e design

Study
Limitations

Conducted in
only one setting,
the small sample
size

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

It does provide some good foundational
information even though the level is a
6.
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Article Title,
Author, etc.
(Current APA
Format)

Article 1
Adewumi et al.,
(2018). Prescribed
Dose of Opioids and
Overdose: A
Systematic Review
and Meta-Analysis of
Unintentional
Prescription Opioid
Overdose. CNS
Drugs, 32(2), 101–
116. https://doiorg.ezproxy.liberty.e
du/10.1007/s40263018-0499-3

Study Purpose

To determine the
doses
of opioids that are
associated with
increased risk of
severe opioid
poisoning or
death.

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

Seven studies out
of 1332 were metaanalyzed

A systemic
review and
meta-analysis.

The result revealed an
increased risk of
unintentional prescripti
on opioid overdose with
20-50 (morphine
milligram equivalents)
MME/day, and
increased risk of fatality
with opioid doses
higher than 50
MME/day.
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Level of
Evidence
(Use
Melnyk
Framewo
rk)

Level 1

Study
Limitations

Varying
definitions of
exposure.
Defined by some
studies as the
filling of
a prescription wh
ile others defined
it as
the prescription o
f an opioid to
the patient.
Also, all studies
assumed that
patients took the
prescribed
opioid.
Consideration
was not given to
other drugs that
can cause an
overdose.

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

This is a prospective study for
evidence-based practice, and patient
education on safe opioid dosages to
prevent harm. I will use this study.
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Article Title,
Author, etc.
(Current APA
Format)

Article 2
Carrico et al., (2018).
The association of
patient satisfactionbased incentives with
primary care
physician opioid
prescribing. Journal
of the American
Board of Family
Medicine:
JABFM, 31(6), 941943.
doi:10.3122/jabfm.20
18.06.180067

Study Purpose

To surmise that
providers who
report being
incentivized based
on patient
satisfaction
surveys are more
likely to report an
impact of such
surveys on their
opioid prescribing
practice.

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

1404 members of
the Colorado
Academy of
Family Physicians.

Methods

Study Results

A survey study

Findings indicate that
among physicians using
patient satisfaction
surveys, incentivized
physicians reported at
least a slight impact on
opioid prescribing 3
times more often than
physicians who were
not incentivized.
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Level of
Evidence
(Use
Melnyk
Framewo
rk)

Level 6

Study
Limitations

Limitations to
this study are; a
low participants’
response rate,
lack of direction
on reported
impact, and selfreport of
physicians
instead of the
assessment of
actual opioid
prescription data.
Further research
is recommended.

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

I will use this study to educate
prescribers on adherence to the CDC
guidelines for opioids prescriptions,
regardless of incentives or patient
survey scores.
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Article Title,
Author, etc.
(Current APA
Format)

Article 3
Coffin, P. O., Santos,
G., Matheson, T.,
Behar, E., Rowe, C.,
Rubin, T., . . .
Vittinghoff, E.
(2017). Behavioral
intervention to reduce
opioid overdose
among high-risk
persons with opioid
use disorder: A pilot
randomized
controlled trial. PloS
One, 12(10),
e0183354.
doi:10.1371/journal.p
one.0183354

Study Purpose

To reduce the
occurrence of
opioid overdose
among high-risk
opioid-dependent
individuals with
the use of
repeated-dose
motivational
interviewing
intervention
(REBOOT),
versus treatments.

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

63 participants
aged 18-65 with a
history of an opioid
use disorder, who
had experienced an
overdose in the
past four months.
67% male, 65%
White, 17%
African-American,
and 14% Latino.

Methods

Study Results

A pilot singleblinded
Randomized
control trial.

The findings revealed
that participants were
less likely to experience
an overdose.
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Level of
Evidence
(Use
Melnyk
Framewo
rk)

Level 2

Study
Limitations

None discussed.
Conducting more
studies to
compare
outcomes could
be beneficial.

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

This study is valid and can be used to
prevent opioid overdose and in some
cases deaths. Yes, I will use this study.
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Article Title,
Author, etc.
(Current APA
Format)

Article 4
Delcher et al., (2015).
Abrupt decline in
oxycodone-caused
mortality after the
implementation of
Florida’s Prescription
Drug Monitoring
Program. Drug And
Alcohol Dependence,
150, 63–68.

Study Purpose

To evaluate the
effects of PDMP
on oxycodonecaused mortality
in the state of
Florida

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

120 repeated
monthly
observations and
monthly counts of
oxycodone-related
deaths, obtained
from the Florida
Medical Examiners
Commission as the
outcome variable.

Methods

A quasiexperimental
research
design

Study Results

Results indicate that for
a system-wide increase
of one PDMP inquiry
per prescriber,
oxycodone-related
deaths declined by
0.229 persons per
month (p=0.002). This
indicates that PDMP
had a significant effect
on decreasing
oxycodone-caused
fatality in Florida.
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Level of
Evidence
(Use
Melnyk
Framewo
rk)

Level 3

Study
Limitations

It will be great to
extend to other
states and
compare
outcomes.
Possible changes
to drug treatment
that impact
oxycodone
decline. Possible
misclassification
of deaths if other
drugs are
involved.

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

Yes, I will use this study despite mixed
feelings about PDMP and its
inconsistent use among states. This
study will serve as a good resource to
promote uniformity and consistency in
opioid prescriptions in all states, to
address the prescription drug epidemic.
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Article Title,
Author, etc.
(Current APA
Format)

Article 5
Finnell et al., (2017).
The role of
continuing medical
education in
increasing enrollment
in prescription drug
monitoring programs.
Clinical
Therapeutics, 39(9),
1896-1902.
doi:http://dx.doi.org.e
zproxy.liberty.edu/10
.1016/j.clinthera.2017
.07.040

Study Purpose

A continuing
medical program
to increase
awareness of the
PDMP and its use.

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

465 clinicians
participated in 1 of
2 webcasts. Only
207 of those
responding to a
pre-survey, and 64
responded to a
post-survey.

Methods

Study Results

A pre- and
postinterventional
study design

The result indicated a
significant likelihood of
increase physician use
of the PDMP after the
educational
intervention.
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Level of
Evidence
(Use
Melnyk
Framewo
rk)

Level 4

Study
Limitations

Despite
increased
clinician
knowledge and
the likelihood of
PDMP usage, the
education did not
result in a
significant
increase in
enrollment in
state PDMPs.

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

Yes, I will use this study. This is a very
good study indicating that education
significantly improved clinician
knowledge about the characteristics of
addiction, and findings in a PDMP that
is suggestive of diversion or abuse.
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Article Title,
Author, etc.
(Current APA
Format)

Article 6
Goedel et al., (2019).
Randomised clinical
trial of an emergency
department-based
peer recovery support
intervention to
increase treatment
uptake and reduce
recurrent overdose
among individuals at
high risk for opioid
overdose: Study
protocol for the
navigator trial. BMJ
Open, 9(11)
doi:http://dx.doi.org.e
zproxy.liberty.edu/10
.1136/bmjopen-2019032052

Study Purpose

To determine the
efficiency of peer
recovery support
intervention to
address opioid
overdose.

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Sample size
(n=650)
High-risk adult
patients presenting
to the ED for
opioid overdose, or
opioid abuserelated problems.

Methods

RCT

Study Results

Findings from this trial
have the potential to
create the evidence base
for peer recovery
support services as an
effective intervention
for fatal and non-fatal
opioid abuse.
This study also
facilitated unlimited
access to data-sharing
between key entities
such as hospitals,
behavioral healthcare
facilities, and
researchers on
overdose-related
morbidity and
mortality.
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Level of
Evidence
(Use
Melnyk
Framewo
rk)

Level 2

Study
Limitations

Databases used
to characterize
the primary
outcomes might
not be
representative
and will fail to
capture resources
of all individuals
who enroll in
OUD treatment
programs,
presenting to
EDs in other
states.

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

Yes. This is a very good study that
strengthens a statewide comprehensive
data-sharing platform to use
administrative records to characterize
the primary outcomes such as OUD
treatment enrolment, recurrent ED
visits. It also gave an insight into the
problem of OUD through the review of
opioid-related morbidity and mortality
data.

INCREASED REPORTING OF PDMP DATA TO ADDRESS OPIOID MISUSE

Article Title,
Author, etc.
(Current APA
Format)

Article 7
Hawk et al., (2018).
Past-year Prescription
Drug Monitoring
Program Opioid
Prescriptions and
Self-reported Opioid
Use in an Emergency
Department
Population With
Opioid Use Disorder.
Academic emergency
medicine: official
journal of the Society
for Academic
Emergency
Medicine, 25(5),
508–516.
https://doi.org/10.111
1/acem.13352

Study Purpose

To evaluate a
relationship
between PDMP
opioid
prescription
records and selfreported nonmedical opioid
use of prescription
opioids in a
cohort of opioiddependent ED
patients enrolled
in a treatment
trial.

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

329 adults meeting
Diagnostic and
Statistical Manual
IV criteria for
opioid dependence,
after reviewing of
PDMP data.

Methods

RCT

Study Results

Results indicate that
36% of patients had at
least one opioid
prescription in the
states’ PDMP. Patients
who reported 15 out of
30 days' use of nonmedical prescription
opioids have a
minimum of four
PDMP opioid
prescriptions (53%)
than patients reporting
1 to 14 days (37%) or
no day of using a nonmedical prescription
opioid (p = 0.002).
Being a female and
having health insurance
coverage have a
significant
representation in the
PDMP (p < 0.05 for
both).
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Level of
Evidence
(Use
Melnyk
Framewo
rk)

Level 2

Study
Limitations

Patients’ opioid
use pattern
changes over
time and that
may not have
been reflected in
this study.
Furthermore,
patients may
obtain a
prescription
under an alias.
Additionally,
PDMPs are
limited to
interstate datasharing
agreements and
may not reflect
all prescriptions
obtained.
Inaccurate data
entry into the
PDMP by
pharmacist or

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

The PDMP may help identify patients
exhibiting risky behavior indicative of
opioid misuse but is incapable of
identifying patients with opioid use
disorder. Yes, I will use this
information because early identification
of opioid misuse warrants prompt
interventions based on patients’ risk
levels.
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Article Title,
Author, etc.
(Current APA
Format)

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results
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Level of
Evidence
(Use
Melnyk
Framewo
rk)

Study
Limitations

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

provider may
result in
erroneous
information.
Article 8
Jefferies, S.
(2018). MedicationAssisted Therapy
Interventions and
Prescription Opioid
Misuse (Order No.
10982632). Available
from ProQuest
Central; ProQuest
Central; ProQuest
Dissertations &
Theses Global.
(2151416647).
Retrieved from
http://ezproxy.liberty.
e
du/login?url=https://s
earch-proquestcom.ezproxy.liberty.e
du/docview/2151416
647?accountid=1208
5

To provide a
systematic review
of literature on the
effectiveness of
medicationassisted therapy
(MAT)
interventions and
psychotherapy in
addressing the
prescription
opioid misuse
within the health
care environment.

15 peer-reviewed
journal articles, 14
were randomized
controlled trials
(RCTs), and 1
quasi-experimental
study.

Systemic
reviews and
meta-analysis
of RCTs

Findings support some
evidence of the
effectiveness of
psychosocial
interventions in
addition to medications,
in the treatment of
opioid dependence.

Level 1

The varying
interventions
used affected the
strength of the
study outcomes.

I will use this study because it
portrayed diverse treatment
interventions. Addressing the opioid
crisis requires multiple strategies for
desirable outcomes.
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Article Title,
Author, etc.
(Current APA
Format)

Article 9
Kelly, Johnson &
Harbison, (2016).
"Pressured to
prescribe" The
impact of economic
and regulatory factors
on South-Eastern ED
physicians when
managing the drugseeking
patient. Journal of
emergencies, trauma,
and shock, 9(2), 58–
63.
https://doi.org/10.410
3/0974-2700.179454

Article 10
Kohlbeck, Akert,
Pace & Zosel, (2018).
A Multistep

Study Purpose

To obtain the
opinions of
Emergency
Department (ED)
physicians,
practicing in the
United States,
about the
economic and
regulatory impact
on managing
patients exhibiting
“drug-seeking”
behavior.

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

141 Emergency
department (ED)
physicians

Methods

A descriptive,
cross-sectional
study

Study Results

71% reported a
perceived pressure to
prescribe opioid
analgesics to avoid
administrative and
regulatory criticism.
The high emphasis
placed on patient
satisfaction scores
impacts their pain
management skills.
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Level of
Evidence
(Use
Melnyk
Framewo
rk)

Level 5

Study
Limitations

Self-reporting of
physicians may
result in the
provision of
inaccurate
information. The
study
participants were
limited to ED
physicians in
Georgia and
Florida. The
potential for bias
exists.

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

This study seems to be on the right
track but needs some modifications to
prevent unnecessary opioid
prescriptions due to poor patient
ratings. Yes, I will use this study
because it provides useful information
to influence administrative guidelines
and practice change.

.

.

To evaluate
provider
knowledge,
attitudes, and
behaviors

Emergency room
providers who
were invited to
participate in an

A multi-step
approach
consisting of
clinicians
survey, a focus

The result revealed an
increase in provider
knowledge about the

Level 4

Self-reporting of
surveys may
create issues
relating to
response or

Yes, I will use this study because it can
be useful for health care organizations,
and the states to emphasize the benefits
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Article Title,
Author, etc.
(Current APA
Format)

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

Approach to Address
Clinician Knowledge,
Attitudes, and
Behavior Around
Opioid Prescribing.
WMJ: Official
Publication of The
State Medical Society
of Wisconsin, 117(1),
38–41. Retrieved
from https://searchebscohostcom.ezproxy.liberty.e
du/login.aspx?direct=
true&db=mnh&AN=
29677414&site=ehos
t-live&scope=site

regarding the
Wisconsin PDMP
before and after
study
interventions.

anonymous online
survey.

group, and a
pre- and
posttests
educational
intervention
study.

PDMP, and foster a
practice change.

Article 11

To use
MedicationAssisted
Treatment (MAT)
interventions to
identify program
structures and
processes to
improve patient

Thirty-five
interventions
including ten RCTs
and 25 quasiexperimental
interventions.

Systemic
review and
meta-analysis

The study revealed that
multidisciplinary and
coordinated care
delivery models are
effective strategies to
implement OUD
treatment and increase

Lagisetty, et al.,
(2017). Primary care
models for treating
opioid use disorders:
What actually works?
A systematic review.
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Level of
Evidence
(Use
Melnyk
Framewo
rk)

Level 1

Study
Limitations

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

recall bias.
Selection bias
due to
participation of
only those
physicians
interested in
PDMP usage or
the opioid crisis.

of the PDMP to clinicians about safe
prescribing practices.

The potential for
bias and
confounding
exists because all
of the studies
were not
randomized
designs.

Yes, I will use this study because of its
strong evidence to improve opioid
misuse disorder through
multidisciplinary coordinated quality
care. It highlights the benefits of
interprofessional collaboration in the
care of patients with OUD.
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Article Title,
Author, etc.
(Current APA
Format)

Study Purpose

Plos One, 12(10),
e0186315.

outcomes, and
guide future
policy
implementation in
the primary care
settings.

Article 12

To critically
evaluate peer‐
reviewed articles
that purposely
identify the ED as
a source of opioid
pain relievers
(OPRs).

Lyapustina et al.,
(2017). The
Contribution of the
Emergency
Department To
Opioid Pain Reliever
Misuse And
Diversion: A Critical
Review. Pain

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results
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Level of
Evidence
(Use
Melnyk
Framewo
rk)

MAT access in primary
care

Emergency
department
physicians who
prescribe pain
killers.

Systemic
literature
review

Results from the study
suggest that the ED is
an important
contributor to both OPR
misuse and diversion of
oxycodone and
hydrocodone.

Study
Limitations

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

Furthermore,
studies published
were limited to
peer reviews,
possibly omitting
interventions that
may be in the
pilot phase or
have outcomes
presented
through other
platforms such as
forums or
webinars.
Level 5

Only two search
engines were
used which
resulted in the
omission of data.
Additionally,
limited
quantitative
studies, make it
difficult to draw
firm conclusions

This is a great study, adherence to the
State and hospital‐based OPR
prescribing guidelines can assist ED
physicians to make reasonable pain
management decisions and also support
them in explaining their decisions to
patients.
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Article Title,
Author, etc.
(Current APA
Format)

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

80

Level of
Evidence
(Use
Melnyk
Framewo
rk)

Practice, 17(8),
1097–1104.
https://doiorg.ezproxy.liberty.e
du/10.1111/papr.125
68

Article 13
McDonald, Carlson
& Jalbert, (2019). An
experimental test of
the effectiveness of
unsolicited reporting
by a prescription drug
monitoring program
in reducing
inappropriate
acquisition of
opioids. Pain
Medicine (Malden,

Study
Limitations

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

about the role of
ED prescribing
in opioid misuse
and diversion
issue.
Furthermore, the
type of medical
provider or
setting was not
consistently
defined.
To determine
whether
prescribers and
pharmacy will
reduce their
prescribing
pattern if they are
notified about
patients who
“doctor shop” for
opioids, through
data obtained
from the PDMP to

All patients
receiving narcotics
for more than four
different Nevada
prescribers and
more than four
pharmacies within
six months.
Intervention group
(N = 436) or
control group
(N = 441).

Control trial

Findings indicate that
eighty-four percent of
prescribers of the
intervention group
discontinued
prescriptions after the
experiment, compared
with 80.5% of the
control group's
prescribers-who were
uninformed.

Level 3

Notification had
minimal effects
in both groups of
patients because
patients found
other prescribers
to continue their
risky drug habits.

This study is promising but requires
some modifications. The more effective
use of the PDMP is to require
prescribers to solicit
patients' prescription histories instead
of proactive notifications.
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Article Title,
Author, etc.
(Current APA
Format)

Study Purpose

Mass.), 20(5), 944954.
doi:http://dx.doi.org.e
zproxy.liberty.edu/10
.1093/pm/pny095

identify these
patients.

Article 14

This is a mixedmethods study to
evaluate
implementation,
enforcement, and
outcomes of the
United States’
laws intended to
restrict high-risk
opioid prescribing
and non-opioid
treatments for
chronic noncancer pain.

McGinty, et al.,
(2018). Protocol: a
mixed-methods study
to evaluate
implementation,
enforcement, and
outcomes of U.S.
state laws intended to
curb high-risk opioid
prescribing.
Implementation
Science, 13, 1.
https://doiorg.ezproxy.liberty.e
du/10.1186/s13012018-0719-8

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Interviews with
key leaders in 18
treatment states to
analyze the timing,
scope, and strength
of each state law’s
implementation
and enforcement

Methods

Study Results

The mixed
design method
of qualitative
analysis study

Variation in law
implementation across
States leads to
inconsistencies. The use
of the PDMP is
recommended with
strong guidelines.
Further study is
recommended for the
consistency of law
enforcement and
outcomes.

81

Level of
Evidence
(Use
Melnyk
Framewo
rk)

Level 5

Study
Limitations

The IQVIA
missed important
data such as
over-the-counter
pain medications
or mail-order
prescriptions.
Furthermore, the
clinical
appropriateness
of pain
treatments and
data on nonclinical pain
management
such as yoga are
missing.

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

I will use this study because it explores
the state laws designed to reduce opioid
prescribing patterns. Once further
studies are completed the results will
hopefully influence the dynamic
policymaking process in various states
to pass, revise, implement, and enforce
laws to address opioid prescribing.
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Article Title,
Author, etc.
(Current APA
Format)

Article 15
Neven et al., (2016).
A Randomized
Controlled Trial of a
Citywide Emergency
Department Care
Coordination
Program to Reduce
Prescription OpioidRelated Emergency
Department Visits.
The Journal of
emergency medicine,
51(5), 498–507.
https://doi.org/10.101
6/j.jemermed.2016.06
.057

Study Purpose

Using a citywide
care coordination
program
combined with an
ED care
coordination
information
system to reduce
ED visits and
decrease opioid
prescriptions to
patients.

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

165 patients with
the most ED visits
for complaints of
pain were
randomized in
three ED hospitals
in metropolitan
Washington.

Methods

Study Results

Randomized
controlled trial
(RCT)

This RCT showed the
effectiveness of a
citywide ED care
coordination program in
reducing ED visits and
controlled substance
prescriptions. PDMP
data indicated that
participants in the
intervention group
received fewer
controlled substance
prescriptions and pills
from all prescribers
than participants in the
normal treatment group.

82

Level of
Evidence
(Use
Melnyk
Framewo
rk)

Level 2

Study
Limitations

Only ED visits
made to the 3
metropolitan
hospitals were
measured,
patients could
have sought
medications
outside the
metropolitan
area. This risk is
low based on
PDMP data
within that
region. The
study failed to
measure patients
who obtain
opioids through
theft, or use
medications of
family or friends,
etc.,

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

This study is very impressive, it
highlights the importance of technology
in monitoring patients’ prescription
habits and aid in reducing frequent ER
visits and decrease opioid prescriptions.
I will use this study.
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Article Title,
Author, etc.
(Current APA
Format)

Article 16
Norwood & Wright,
(2016). Promoting
consistent use of
prescription drug
monitoring programs
(PDMP) in outpatient
pharmacies:
Removing
administrative
barriers and
increasing awareness
of Rx drug abuse.
Research in Social &
Administrative
Pharmacy: RSAP,
12(3), 509–514.
https://doiorg.ezproxy.liberty.e
du/10.1016/j.sapharm
.2015.07.008
Article 17

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

83

Level of
Evidence
(Use
Melnyk
Framewo
rk)

Study
Limitations

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

To identify
barriers to PDMP
use in outpatient
pharmacies and
determine the
impact these
barriers have on
its utilization.

1000 outpatient
pharmacists

A crosssectional study
design

The results revealed
that outpatient
pharmacists were 10
times more likely to
report using the
(PDMP) INSPECT if
they were extremely
concerned with
prescription drug abuse
as compared to those
who were not
concerned at all.

Level 5

The study was
conducted in
only one state,
and therefore
cannot be
generalized. The
response rates of
the survey were
also low which
can lead to bias.

Yes, I will use this study to help
develop strategies to improve the
utilization of PDMPs and explore
innovative ways to limit barriers and
increase outpatient pharmacists'
awareness of prescription drug abuse
and misuse within the community.

To evaluate the
practicality of an
educational

Internal medicine
residents

Pre and posttest

The implementation of
this educational
intervention was

Level 4

Only students at
one program
studied. The

A very good study to implement in all
medical programs to nurture
appropriate opioid prescribing skills
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Article Title,
Author, etc.
(Current APA
Format)

Study Purpose

Raheemullah,
Andruska, Saeed, &
Kumar, (2020).
Improving residency
education on chronic
pain and opioid use
disorder: Evaluation
of CDC guidelinebased education.
Substance use &
Misuse, 55(4), 684690.
doi:http://dx.doi.org.e
zproxy.liberty.edu/10
.1080/10826084.2019
.1691600

program to assess
opioid-prescribing
practices and pain
management
skills of residents
without faculty
involvement.

Article 18

To determine the
effectiveness of
PDMP in
reducing opioidrelated harms and
consequences,

Rhodes et al., (2019).
The effectiveness of
prescription drug
monitoring programs
at reducing opioidrelated harms and
consequences: a

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

22 studies (49
PDMPs)

Methods

Study Results

interventional
study design.

practical. Surveys
indicated an
improvement in
residents’ confidence in
detecting and managing
addiction and improved
prescribing practices
and adherence to CDC
recommendations.

A Systemic
Review

No evidence was found
to strongly support the
overall effectiveness of
PDMPs in reducing
opioid-related
consequences and
harms. However, they
act as a reminder to
physicians to use

84

Level of
Evidence
(Use
Melnyk
Framewo
rk)

Level 5

Study
Limitations

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

number of
participants and
their year of
study not
mentioned. This
can also be
extended to other
programs.

and adherence to national prescription
guidelines. I will use this study.

Diverse study
types result in
inconsistent
results. Review
of literature
conducted in
2014, more
recent

Yes, I will consider this study because
it can trigger further investigation and
development of the PDMP as an
evidence-based tool to help combat the
opioid crisis.
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Article Title,
Author, etc.
(Current APA
Format)

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

systematic review.
BMC Health Services
Research, 19(1), 784.
https://doiorg.ezproxy.liberty.e
du/10.1186/s12913019-4642-8
Article 19
Strand, Eukel &
Burck, (2019).
Moving opioid
misuse prevention
upstream: A pilot
study of community
pharmacists
screening for opioid
misuse risk. Research
in Social &
Administrative
Pharmacy, 15(8),
1032–1036.
https://doiorg.ezproxy.liberty.e

Study Results

85

Level of
Evidence
(Use
Melnyk
Framewo
rk)

caution when
prescribing opioids.

To design the
Opioid Misuse
Risk Prevention
Toolkit and then
evaluate its use by
implementing it in
community
pharmacy practice
sites.

Eleven pharmacists
trained to use the
opioid misuse
toolkit which was
implemented
afterward in their
community to
screen all patients
receiving
prescription
opioids for opioid
misuse behaviors
through the PDMP.

Pilot study

Participating
pharmacists expressed a
preference for this
toolkit as an objective
measurement of
potential opioid misuse
than sole reliance on
professional judgment.
The study also revealed
that 26% of individuals
receiving opioid
prescriptions were
identified as showing
some risk of misuse and
30% at risk of an
accidental overdose.

Study
Limitations

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

information
could be omitted.

Level 4

This pilot project
has no statistical
weight,
therefore, results
should be viewed
from a
qualitative
perspective.
Selection bias is
possible due to
the convenience
sampling of
patientparticipants. A
recall bias also
exists since this
is a self-reported
tool and a

The report of this case study
demonstrated the utility and the
feasibility of opioid misuse risk
screening at the community pharmacy
level and in enhancing conversations
between patients and pharmacists.

INCREASED REPORTING OF PDMP DATA TO ADDRESS OPIOID MISUSE

Article Title,
Author, etc.
(Current APA
Format)

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

86

Level of
Evidence
(Use
Melnyk
Framewo
rk)

du/10.1016/j.sapharm
.2018.07.011

Article 20
Turner, Caetano &
Tannenbaum, (2019).
Leveraging policy to
reduce chronic opioid
use by educating and
empowering
community-dwelling
adults: a study
protocol for the
TAPERING
randomized
controlled trial.
Trials, 20(1), N.PAG.
https://doiorg.ezproxy.liberty.e
du/10.1186/s13063019-3508-z

Study
Limitations

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

possibility of
response bias
due to insincere
responses from
patients.
To test the
efficiency of a
population-based,
wide-scale,
government-led
direct-to-patient
educational
pamphlet
(intervention arm)
to decrease
chronic opioid use
among adults in
the community
compared to usual
care (control arm).

Chronic opioid
users across
Manitoba

A prospective,
clusterrandomized,
parallel-arm
controlled
trial.

This fosters
communication
between patients and
providers about their
opioid use and
alternative pain
treatments.
Furthermore, a
reduction in
inappropriate
prescriptions of
sedative-hypnotic and
non-steroidal antiinflammatory drugs
(NSAID) was evident.
Results from this trial
will serve as a guide for
future use in the
community.

Level 2
.

Information on
the indication of
drug use was
missing for some
medications.
Possible
selection bias
due to faulty
participant
identification
process. Codeine
and tramadol
were excluded as
opioids and can
be considered
safe, potentially
leading to
increased

Yes, this seems like a promising
intervention to address the opioid crisis.
A good study for implementation into
practice.
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Article Title,
Author, etc.
(Current APA
Format)

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

87

Level of
Evidence
(Use
Melnyk
Framewo
rk)

Study
Limitations

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

prescription and
overdose.
Article 21
Wilson, et al., (2019).
The utility of a
statewide prescription
drug-monitoring
database vs the
Current Opioid
Misuse Measure for
identifying drugaberrant behaviors in
emergency
department patients
already on opioids.
The American
Journal of
Emergency
Medicine, 158250.
https://doiorg.ezproxy.liberty.e

To compare the
PDMP and the
Current Opioid
Misuse Measure
(COMM), a
commonlyrecommended
screening tool in
detecting drugaberrant behaviors
in patients
currently on
opioids at the time
of their ED visit.

Patients on opioids
who were enrolled
prospectively in a
mixed urbansuburban ED
seeing.

A prospective
study

The study reveals that
the PDMP by itself is a
more useful screening
instrument than either
the COMM or
combination of both for
patients already taking
opioids at the time of
their ED visit

Level 4

The PDMP
misses a majority
of patients with
documented
drug-aberrant
behaviors in the
EMR, and
should not be
used in isolation
to justify
whether a
particular opioid
prescription is
appropriate.

Yes, I will use this study because it
identifies PDMP as a strong screening
tool for opioid misuse behaviors.
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Article Title,
Author, etc.
(Current APA
Format)

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

88

Level of
Evidence
(Use
Melnyk
Framewo
rk)

Study
Limitations

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.

du/10.1016/j.ajem.20
19.05.035
Article 22
Yang, Xu & He,
(2018). Efficacy and
feasibility of opioids
for burn analgesia:
An evidence-based
qualitative review of
randomized
controlled
trials. Burns, 44(2),
241-248.
doi:10.1016/j.burns.2
017.10.012
Article 23
Young, Crausman &
Fulton, (2018).
Suboptimal opioid
prescribing: A
practice change
project. Rhode Island

To assess the
literature
regarding the
effectiveness and
side effects of
opioids both in
adult and pediatric
burn patients.

Adult and pediatric
patients with burns.

A systemic
review of
RCTs

The results revealed
that topical morphine
application alleviates
burn-related pain and
anxiety. Opioid-related
side effects also
decreased over time.

Level 1

Results from a
small sample
size in the trials
are not strong
enough to
convince. Also,
most of the
RCTs were over
ten years old and
may have lacked
updated
information.

Yes, I will use this study because the
results of the study are the intended
outcome however, increased sample
size and review of current literature
will provide more convincing results.

To limit opioid
prescribing in
urgent care
settings, focusing
on the treatment
of acute pain.

14 physicians in
four privately
owned urgent care
centers

A Pilot study

An immediate decline
was noted in the
average number of
opioid prescriptions
written per provider per
week throughout the
pilot.

Level 4

This is a Pilot
study;
prescribers can
go back to
unsafe
prescribing
practices after
the study end.

Yes, I will use this study because it
made a connection between increased
prescribing and increased opioid
addiction. Furthermore, it highlighted
the use of prescribed opioids and heroin
which is troubling and warrants
immediate intervention.
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Article Title,
Author, etc.
(Current APA
Format)

Medical Journal
(2013), 101(2), 41.

Study Purpose

Sample
(Characteristics of
the Sample:
Demographics,
etc.)

Methods

Study Results

89

Level of
Evidence
(Use
Melnyk
Framewo
rk)

Study
Limitations

Provider
awareness and
education is the
key.

Would Use as Evidence to Support a
Change? (Yes or No) Provide
Rationale.
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Appendix B

Identification

PRISMA 2009 Flow Diagram

Records identified through database
searching (n=50, 292)

Additional records identified
through other sources
(n = 2616)

Included

Eligibility

Screening

(n = 50, 292)
Records after duplicates removed
(n = 163)

Records screened
(n = 39)

Records excluded
(n = 12)

Full-text articles assessed
for eligibility
(n =27)

Full-text articles excluded,
with reasons
(n = 4) weak evidence

Studies included in
qualitative synthesis
(n = 19)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 4)
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Appendix C
IRB Exemption Email

From: irb@liberty.edu <irb@liberty.edu>
Sent: Friday, May 29, 2020 2:38 PM
To: Georgestone, Claudia <cgeorgestone@liberty.edu>; Sanders, Lynne Shurbet (Doctoral Nursing)
<lsanders@liberty.edu>
Subject: IRB-FY19-20-407 - Initial: Initial - Non-Human Subjects Research
May 29, 2020
Claudia Georgestone
Lynne Sanders
Re: IRB Application - IRB-FY19-20-407 The efficient use of the PDMP for increased reporting of opioid
misuse
Dear Claudia Georgestone, Lynne Sanders:
The Liberty University Institutional Review Board (IRB) has reviewed your application in accordance
with the Office for Human Research Protections (OHRP) and Food and Drug Administration (FDA)
regulations and finds your study does not classify as human subjects research. This means you may begin
your research with the data safeguarding methods mentioned in your IRB application.
Decision: No Human Subjects Research
Explanation: Your study is not considered human subjects research because it will not involve the
collection of identifiable, private information.
Please note that this decision only applies to your current research application, and any modifications to
your protocol must be reported to the Liberty University IRB for verification of continued non-human
subjects research status. You may report these changes by completing a modification submission through
your Cayuse IRB account.
If you have any questions about this determination or need assistance in determining whether possible
modifications to your protocol would change your application's status, please email us at irb@liberty.edu.

Sincerely,
G. Michele Baker, MA, CIP
Administrative Chair of Institutional Research
Research Ethics Office
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